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ABSTRACT 
The metabolic adaptation is now considered a new hallmark of cancer, in 
which cancer cells exhibit high rates of glucose consumption and consequent 
lactate production. To ensure the rapid efflux of lactate, most of cancer cells 
express high levels of monocarboxylate transporters (MCTs). It has long been 
recognized that MCTs might represent good targets for chemotherapy and several 
in vitro studies have shown the potential of this approach, however, regarding 
prostate cancer the impact of MCTs inhibition and their regulation during prostate 
cancer progression still largely unknown. Also, it remains unclear what is the 
predominant metabolic pathway in prostate cancer and therefore which pathway 
represents the most appropriate target for PCa therapy. 
The major aim of this thesis was to investigate MCTs expression and regulation 
during prostate cancer progression and whether these transporters could 
represent promising targets for prostate cancer treatment.  
MCTs expression together with other key metabolic-related proteins was 
studied in a large series of human prostate tissues and its clinico-pathological 
value was assessed. In vitro studies were then carried in order to understand how 
metabolic demands change during prostate cancer progression and how these 
changes could represent promising targets for prostate cancer disease, with a 
special emphasis to MCTs in this context.  
The obtained results indicate that prostate cancer is not as glycolytic as 
other tumour types and increased glycolysis is mainly found in a most advanced 
stage of the disease. Due to this, we observed that different isoforms of MCTs are 
differentially expressed across prostate cancer progression and accordingly to the 
demands of prostate cancer cells at each stage. We showed that MCTs are not 
restricted to the plasma membrane of prostate cells, indicating their involvement in 
alternative cellular roles different from glycolysis. Finally, we showed that MCTs 
inhibition affects viability and proliferation of prostate cancer cell lines under 
different tumour environment conditions. 
In conclusion, the results presented in this thesis have an important impact 
on the comprehension of the metabolic demands of prostate cancer tumours 
during disease progression in which MCTs play an important role and might 
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represent promising therapeutic targets in different phases of neoplastic 
transformation and progression.  
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RESUMO 
O conceito de alterações metabólicas sofridas pelas células tumorais foi 
recentemente incluído nas principais alterações sofridas no cotexto de 
transformação maligna. Uma das principais características metabólicas das 
células tumorais consiste no seu elevado consumo de glucose e consequente 
produção de lactato.  
De modo a assegurar o rápido efluxo de lactato, a maioria das células 
malignas expressam elevados níveis de transportadores de monocarboxilatos 
(MCTs). A inibição destes transportadores tem sido apresentada como um bom 
alvo para quimioterapia e vários estudos in vitro demonstraram já o potencial 
desta abordagem, no entanto, no contexto do carcinoma da próstata o impacto da 
inibição MCTs assim como a sua regulação durante a progressão tumoral 
continua em grande parte desconhecida. Adicionalmente, ainda não está claro 
qual é a via metabólica predominante no cancro da próstata e, portanto, qual a 
que se apresenta como alvo mais apropriado para a terapia. 
O principal objetivo deste trabalho foi investigar a expressão e regulação dos 
MCTs durante a progressão do carcinoma da próstata e se estes transportadores 
poderiam representar alvos promissores no tratamento desta doença. 
A expressão de MCTs juntamente com outras proteínas relacionadas com o 
metabolismo foi estudada usando uma grande série de tecidos de próstata 
humana e o seu valor clínico-patológico foi avaliado. Estudos in vitro foram 
realizados a fim de compreender como variam as exigências metabólicas das 
células durante a progressão tumoral e de que forma estas mudanças poderiam 
representar alvos terapêuticos para a doença, dando especial ênfase aos MCTs 
neste contexto. 
Os resultados obtidos indicam que o carcinoma da próstata não é tão glicolítico 
como outros tipos de tumor e que o aumento da glicólise é principalmente 
encontrado num estadio mais avançado da doença. Foi observado que diferentes 
isoformas de MCTs estão diferencialmente expressas em diversas fases de 
progressão do carcinoma da próstata e potencialmente relacionados com 
diferentes vias metabólicas e portanto não restritas ao seu clássico papel de 
transportadores de lactato na membrana citoplasmática e que a inibição das 
diferentes isoformas em diferentes condições afeta a viabilidade e proliferação 
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das células malignas. Em conclusão, os resultados apresentados nesta tese são 
pioneiros na compreensão das exigências metabólicas do carcinoma da próstata 
durante a progressão tumoral, contextualizando os MCTs como possíveis alvos 
terapêuticos em diferentes fases da transformação neoplásica e progressão 
maligna. 
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AIMS AND THESIS LAYOUT 
 
Metabolic changes during malignant transformation have been noted for many 
years. Otto Warburg first reported that cancer cells preferentially rely on glycolysis 
for energy production, even in the presence of oxygen, leading to production of 
high levels of lactate. The crucial role of lactate efflux and exchange within the 
tumour microenvironment drew attention to monocarboxylate transporters (MCTs). 
MCTs have been pointed as promising targets in cancer therapy and described in 
a large variety of tumours, however, studies showing how these isoforms 
contribute to the acquisition of the malignant phenotype are scarce and regarding 
prostate cancer it is totally unknown.   
The main aim of this thesis was to characterize MCTs expression in prostate 
tissues, namely prostate cancer, as well as to give a contribution to understand the 
role of MCTs in prostate cancer maintenance and progression providing evidence 
for the exploitation of MCTs as potential targets for prostate cancer therapy. 
This thesis is organized in 7 related chapters, aiming to show the most important 
results obtained during the development of this scientific project. 
In Chapter 1 a general introduction to the Hallmarks of cancer with a special 
emphasis to altered cellular metabolism as a new hallmark of cancer and the 
“Warburg effect” as the basis to explore MCTs as suitable targets for cancer 
therapy is provided. Also, the current knowledge on prostate cancer metabolism is 
reviewed in this chapter.  
In Chapters 2-6 major findings about metabolic changes across prostate cancer 
malignant transformation as well as the value of using MCTs as targets for 
prostate cancer therapy is presented. These chapters include results already 
published or submitted for publication in international scientific periodicals with 
referees, giving a contribution to understand the role of MCTs in the context of 
prostate cancer. In Chapter 2 the expression of MCTs in prostate tissues and the 
clinico-pathological value of this expression is presented. Chapter 3 explores 
more deeply the role of MCT2 in prostate cancer metabolism. In Chapter 4 a 
panel of key metabolic-related proteins expression was studied in an even bigger 
casuistic of prostate tissues. In vitro assays were also performed showing 
  
 
    vii 
important metabolic alterations across prostate cancer malignant transformation 
and how MCTs inhibition affects prostate cancer cells in different tumour 
environment condition. In Chapter 5 an effort to understand the metabolic 
alterations in the stroma that surrounds prostate tumours is presented. Finally, 
Chapter 6 presents an insight on MCTs regulation across prostate cancer 
progression and in Chapter 7, the main conclusions of Chapters 2-6 are 
summarized and some important future directions are suggested. Each of these 
chapters has their own bibliography section.  
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CHAPTER 1. GENERAL INTRODUCTION 
 
1.1 Reprogramming of energy metabolism as an emerging Hallmark of 
Cancer 
Advances in cancer research have generated a rich but also extremely 
complex knowledge revealing cancer as a disease that involves several dynamic 
changes.  In order to organize the complexity of cancer, the biological capabilities 
acquired during the multistep development of human tumours and shared by all 
cancers were grouped and denominated as the “hallmarks of cancer”. Sustaining 
proliferative signaling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, and activating invasion and 
metastasis were the traits established in order to create an organized principle that 
provides a logical framework to understand the diversity of neoplastic disease [1]. 
Lately, new hallmarks have emerged and reprogramming of energy metabolism 
was considered an emerging hallmark of cancer since it was recognized that the 
chronic and uncontrolled cell proliferation that represents the essence of 
neoplastic disease involves also adjustments of energy metabolism in order to fuel 
cell growth and division [2]. Figure 1 represents the last version of the “Hallmarks 
of cancer”. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The Hallmarks of Cancer [2]. 
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1.1.1 The Warburg effect as the basis to explore altered cellular metabolism 
in cancer 
 
Altered energy metabolism is being proved to be as widespread in cancer cells as 
many of the other cancer-associated traits that have been accepted as hallmarks 
of cancer. However just recently a major relevance has been given to cancer 
metabolism,  the observation that tumour cells exhibit an altered metabolism  
when compared to normal cells was made almost one century ago by the Nobel 
Prize winner Otto Warburg who described it as the first tumour specific-alteration 
[3]. Warburg described that in contrast to non-malignant cells, many types of 
cancer cells prefer glycolysis as the ATP source, even in the presence of 
abundant oxygen.  If under aerobic conditions, normal cells process glucose, ﬁrst 
to pyruvate via glycolysis in the cytosol and then to carbon dioxide in the 
mitochondria, under anaerobic conditions, glycolysis is favored and few pyruvate 
is send to the oxygen-consuming mitochondria. Warburg ﬁrst observed that cancer 
cells can reprogram their glucose metabolism, and thus their energy production, 
by limiting their energy metabolism largely to glycolysis, leading to a state that has 
been called ‘‘aerobic glycolysis’’ (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic representation of the differences between OXPHOS, anaerobic glycolysis and 
“aerobic glycolysis” (Warburg effect) [4]. 
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Glycolysis, the first major pathway of cellular metabolism, occurs in the cytoplasm 
and is functional even in the absence of oxygen. While glycolysis is able to 
produce ATP at high rates, it is considered a low efficiency pathway because it 
produces only two ATP molecules per glucose. In order to compensate for the 
lower efﬁciency of ATP production obtained by glycolysis relative to mitochondrial 
oxidative phosphorylation, cancer cells markedly increased uptake and utilization 
of glucose in many human tumor types being the rate of entry higher than in 
normal cells [5-7]. This has proven useful to detect tumours and also monitor their 
treatment, as it is the basis for the clinical use of positron emission tomography 
(PET) that uses a radiolabeled analog of glucose (18F-ﬂuorodeoxyglucose, FDG) 
as a reporter [8]. FDG is recognized as a substrate for glucose transport systems; 
thus, the rate of entry of this glucose derivate into cells is determined by the 
activity of glucose transport systems. Inside the cells, the accumulation of the 
radioactive glucose analogue serves as a read-out for the rate of glucose entry 
into cells. Since tumour cells exhibit enhanced glucose uptake compared to 
adjacent normal cells, PET is able to detect tumours and differentiate them from 
normal tissue [9, 10] (Figure 3). 
 
 
 
 
 
 
 
 
 
 
Figure 3. PET imaging with FDG of a patient with lymphoma. The mediastinal nodes (purple arrow) 
and supravincular nodes (green arrows) show high uptake of FDG, showing that tumours in these 
nodes have high levels of FDG uptake. The bladder (yellow arrow) also has high activity, because 
of excretion of the radionuclide [11]. 
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1.1.2 A metabolic switch that confers advantage to cancer cells. 
 
1.1.2.1 Why do cancer cells prefer aerobic glycolysis? 
 
Why a cell would settle for two molecules of ATP per molecule of glucose rather 
than the additional 34 molecules of ATP from aerobic pathways remains hotly 
debated. Numerous explanations have been presented including hypoxic 
selection, mitochondrial dysfunction, AKT activation, and deactivation of the 
tumour suppressor p53 but none can be generalized to all cell types or types of 
cancer and a combination of mechanisms are likely to be involved. 
The original explanation of Otto Warburg for aerobic glycolysis in cancer cells was 
irreversible damage of the respiratory chain [3]. Mitochondria are indeed the most 
important component of the cell and it is known that mitochondrial DNA (mtDNA) 
mutations and deletions can occur in some contexts where aerobic glycolysis is 
observed. Alternatively, it is perhaps more likely that the primary metabolic lesion 
is a deregulation of mitochondrial biogenesis: cancer cells may derive the majority 
of their ATP from the glycolytic pathway because they do not have a sufficient 
number of otherwise normal mitochondria to yield ATP from oxidative metabolism.  
In fact, many cancer cells have fewer mitochondria per cell in comparison to 
healthy cells [12]. Another hypothesis has come over in the last years, such as the 
somatic evolution during carcinogenesis that involves changes in the activity of 
tumour suppressor genes and proto-oncogenes. It is known that some mutations 
confer a selective advantage to cancer cells, and contribute to malignant 
transformation. Molecular alterations over the evolution of carcinogenesis are 
driven by selective pressure within the cellular microenvironment. Early in 
tumorigenesis, prior to vascularization, the cells in the center of the tumour are 
unable to access oxygen and nutrients from the bloodstream and experience 
periods of intermittent hypoxia. Enhanced glycolysis, under such circumstances, 
may benefit the cell in two ways: 1) by maintaining ATP production when oxygen is 
limiting, and 2) by producing reducing equivalents that protect the cell from 
oxidative stress during periods of reoxygenation [13]. However, cancer cells 
maintain their glycolytic phenotype following vascularization. Therefore, selection 
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for cancer genotypes that improve glycolysis under anaerobic conditions may 
result in a genotype that must rely on glycolysis even under aerobic conditions. 
While these observations are widespread, their molecular underpinnings are 
complex and not well defined so far. 
Several reasons were established in order to explain what drives this glycolytic 
switch in cancer cells and how it constitutes an advantage for tumour growth. 
Some explanations are presented below:  
 
- Tumour cells are able to survive in conditions of fluctuating oxygen tension, 
condition that would be lethal for cells that rely mostly on OXPHOS to 
generate ATP [10, 14]. 
- The acids produced by cancer cells, namely lactic acid, condition their 
environment, favouring tumour invasion and suppress anticancer immune 
effectors. Moreover, lactate can be taken up by stromal cells to regenerate 
pyruvate that either can be extruded to refuel the cancer cell or can be used 
for OXPHOS. The metabolic netwok established by anaerobic components 
(cancer cells) and aerobic components (nontransformed stromal cells) 
allows buffering and recycling products of anaerobic metabolism to sustain 
cancer cell survival and growth [15-17]. 
- Tumours are able to metabolize glucose through the pentose phosphate 
pathway to generate NADPH thus supplying cells’ anti-oxidant defenses 
against hostile microenvironment and chemotherapeutic agents. NADPH 
can also contribute to fatty acid synthesis [13]. 
- Cancer cells use intermediates of the glycolytic pathway for anabolic 
reactions: glucose 6-phosphate for glycogen and ribose 5-phosphate 
synthesis, dihydroxyacetone phosphate for triacylglyceride and 
phospholipid synthesis, and pyruvate for alanine and malate sunthesis. 
Moreover, pyruvate may enter a truncated tricarboxylic acid cycle. The 
resultant acetyl-CoA is exported from the mitochondrial matrix and 
becomes available for the synthesis of fatty acids, cholesterol, and 
isoprenoids [10, 13]. 
- Reduced ATP generation in mitochondria is a compromise that tumour cells 
have to make in order to initiate oncogenic transformation. Tumour cells 
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partially inhibit OXPHOS, thus reducing ATP production, and do not allow 
electrons to enter in the electron transport chain all the way to oxygen. 
Consequently, the generation of reactive oxygen species (ROS) increase 
causing mutations in proto-oncogenes to initiate tumorigenesis [18, 19]. 
 
Importantly, recent evidence showed that some tumors have been found to 
contain distinct subpopulations of cancer cells that differ in their energy-
generating pathways. One subpopulation consists of glucose-dependent cells 
that consume high levels of glucose and secrete high levels of lactate 
(‘‘Warburg-effect’’), whereas the other subpopulation preferentially utilize the 
lactate produced by the other cells as their main energy source, employing part 
of the citric acid cycle to do so. As so, the hypoxic cancer cells rely on glucose 
for fuel and secrete lactate as waste, this lactate is then imported and 
preferentially used as fuel by their better-oxygenated cells creating an 
energetic symbiosis in which lactate is the major player and that represents 
advantages for the sustaining and progression of the tumours. 
Figure 4 shows a model for cell-environment interactions in carcinogenesis. 
First, it results in a phenotype with a powerful proliferative advantage, in that, 
through persistent aerobic glycolysis, it is able to alter the local 
microenvironment in a way that is harmless to itself, but fatal to competing 
populations. Secondly, acidification of the microenvironment facilitates tumour 
invasion both through destruction of adjacent normal populations and through 
acid-induced degradation of the ECM and promotion of angiogenesis [11]. 
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Figure 4.  Model for cell-environment interactions in carcinogenesis (from [11]). Cell colours 
represent different cell types: grey for normal epithelial cells, pink for hyper-proliferative cells, blue 
for hypoxic cells, green for glycolytic cells and yellow for motile cells. Light orange nuclei represent 
one mutation while dark orange nuclei represents more than one mutation. Blebbing membranes 
show apoptotic cells.  
 
1.1.2.2 A deeper insight into Hypoxia and Lactate export: Great contributors 
to malignancy. 
 
Tumour hypoxia is a common feature of malignancy in solid tumours that is also 
emerging progressively as a common feature of prostate tumours associated with 
poor prognosis. The molecular basis of hypoxia in disease progression is well 
documented, however, the potential role of hypoxia in these processes remains 
poorly understood.  
It is well documented that in response to an adverse microenvironment cancer 
cells initiate responsive mechanisms that favors cell survival and migration, 
namely the activation of the transcriptional factor HIF-1alpha, a widely known 
regulator of hypoxic stress, which has been associated with cancer progression 
[20-25]. HIF-1alpha subunit is degraded in the presence of oxygen and stabilized 
under hypoxic conditions (<5%O2) and translocated to the nucleus forming a 
HIF1alpha/beta complex which can bind to target genes on their hypoxic response 
elements (HREs) [26, 27]. This biding results in a transcriptional up-regulation of 
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target genes that mediate multiple adaptations that leads to resistance to hypoxic 
conditions, namely, genes involved in the glycolytic pathway, as well as the 
vascular endothelial factor (VEGF) that promotes angiogenesis [10, 28]. Figure 5 
shows representative scheme of HIF-1alpha degradation under normoxic 
conditions and is activation by hypoxia [29]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Scheme representing HIF-1alpha degradation under normoxic conitions and is activation 
by hypoxia. Under normoxia HIF-1alpha is hydroxylated, ubiquitinated and consequently 
depredated. Under hypoxic conditions HIF-1alpha protein is expressed, migrates to the nucleus 
and binds to HIF-1beta and further to HRE inpromoting regions, inducing glycolysis, angiogenesis, 
erytropoiesis and vasomotion [29]. 
 
Therefore, adaptation to hypoxia and acidosis will force the emergence of an 
adaptive phenotype with constitutive up-regulation of glycolysis and resistance to 
acid-induced toxicity that will invade the normoxic regions and breach the 
basement membrane towards invasion. Hence, aerobic glycolysis, a common 
feature in primary tumours, is pointed as a feature required for evolution of 
invasive human cancers. 
Importantly, HIF-1 alpha not only stimulates glycolysis but also decreases 
oxidative phosphorylation. In a general way, HIF can compromises oxygen 
consumption by induction of pyruvate dehydrogenase kinase-1 (PDK1) 
expression, which inhibits the mitochondrial pyruvate dehydrogenase (PDH), 
preventing conversion of pyruvate into acetyl-CoA and consequently its diversion o 
the respiratory pathway (Figure 6). As a consequence of this, hypoxic tumour cells 
are forced as well to increase the glycolytic metabolism to maintain the production 
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of ATP for cell survival. As so, HIF1-alpha regulates the expression of glucose 
transporters, namely, GLUT-1 and GLUT-3 to increase glucose uptake and also 
indces the expression of several other proteins involved in this metabolic cascade, 
such as, hexokinase II (HK2) and pyruvate kinase type 2 (PKM2). This metabolic 
reprogramming mediated by HIF1-alpha redirects pyruvate to another HIF1-alpha 
target, lactate dehydrogenase (LDHA), responsible for the conversion of pyruvate 
to lactate. Lactate production contributes to acidosis in the tumour 
microenvironment and therefore to the acid-resistant phenotype leading to an 
increase in proteins that perform the pH regulation, namely carbonic anhydrase IX  
(CAIX), which performs the reversible conversion of CO2 to bicarbonate and 
proton, contributing to extracellular acidification of tumour microenvironment and 
consequently to control intracellular pH, being considered a hypoxic marker and a 
prognostic indicator [27, 30].  
Due to all this reasons hypoxia induced metabolic changes represent promising 
therapeutic targets for cancer therapy with some clinical trials already in course. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. HIF1-alpha expression promotes the expression of various proteins involved in glycolytic 
metabolism [31]. 
 
The lactate produced as an end product of glycolysis is largely associated with 
poor prognosis, disease-free survival and overall survival in several cancers 
including prostate cancer [32-34]. Evidence shows that independently of the 
oxygen condition, lactate can regulate hypoxia inducible genes by stimulating the 
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accumulation of HIF1-alpha, which would lead in turn to a stimulation of the 
glycolytic pathway by regulating glycolytic enzymes, providing an important 
positive feedback in the context of cancer. Moreover, lactate was demonstrated to 
stimulate molecules involved in the process of cancer invasion and metastasis. 
CD44, VEGF and transforming growth factor (TGFB2) are some of them [35-39]. 
Besides glycolysis, it is important to recognize that there are other pathways that 
can also contribute to lactate production in solid tumours such as glutaminolysis 
and serinolysis (Figure 7) [40,41]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Overview of the metabolic pathways leading to lactate production in cells (continuous 
lines). The discontinuous arrows indicate lactate uptake and flow inside oxidative cancer cells. 
 
Besides being mainly an end-product, lactate exported might also be a substrate 
for neighbor cells, a phenomenon known as “cell-cell lactate shuttle”, in which the 
peripheral and oxygenated oxidative cells consume the lactate produced by the 
central and hypoxic glycolytic cells (Figure 8). 
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Figure 8. Scheme representing intratumoural hypoxia and metabolic symbiosis.   
 
 
The crucial role of lactate efflux and exchange within the tumour 
microenvironment, drew attention to monocarboxylate transporters (MCTs) which 
transport monocarboxylates such as lactate across the membranes, and therefore 
play a central role in cellular metabolism and metabolic communication between 
tissues.   
 
1.2 Monocarboxylate Transporters (MCTs) in the context of cellular 
metabolism. 
 
The transport of monocarboxylates across the plasma membrane was originally 
thought to be via non-ionic diffusion of the free acid, however, the demonstration 
that lactate and pyruvate transport into human erythrocytes could be strongly 
inhibited after treatment with chemicals, allowed the identification of a specific 
monocarboxylate transport mechanism. The monocarboxylate transport was then 
characterized extensively in different cell types and the observed characteristics 
led to the rationale for  of the existence of a family of monocarboxylate 
transporters [42-43]. 
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1.2.1 The MCT Family 
 
MCTs are encoded by the SLC16 gene family, which is conserved among species, 
including rat, mouse, chicken and others. The family is presently composed by 14 
members, identified through screening of genomic and expressed sequence tag 
databases [43]. 
These proteins catalyse the transport  of lactate with a proton, with no energy input 
involved in this process [42, 44].  
It is predicted that the topology of MCTs consists of 12 transmembrane domains 
(TMDs) with the N- and C- termini located in the cytoplasm, as illustrated in Figure 
9 for MCT1. The TMDs are highly conserved among isoforms with the greatest 
sequence variations observed in the C-terminus and the large intracellular loop 
between TMDs 6 and 7, which has a range of 29-105 amino acid residues [45] . 
This observed variability is common to transporters with 12 TMDs and it is thought 
that these sequence variations are related to substrate specificity or regulation of 
transport activity [44, 45]. Theoretical predictions and experimental evidence 
indicate that none of the MCT family members is glycosylated [46-49]. To function, 
an MCT translocates a proton and a monocarboxylate through the plasma 
membrane by an ordered mechanism in which H+ binding is followed by 
monocarboxylate binding to the protonated transporter [49, 50]. Therefore, MCT 
activity is dependent on both besides substrate concentration and proton gradient 
between the extracellular and intracellular milieus.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.  Proposed topology of MCT1. The model shown is that predicted from the primary 
sequence using hydropathy plots and subsequently confirmed by proteolytic cleavage and labelling 
experiments as described by Juel & Halestrap [44]. 
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Lactate is indeed the monocarboxylate whose transport across the plasma 
membrane is quantitatively more important, however, MCTs are also important for 
the transport of many other metabolically important monocarboxylates such as 
pyruvate, the branched-chain oxoacids derived from leucine, valine and isoleucine, 
and the ketone bodies acetoacetate, β-hydroxybutyrate and acetate [45]. 
Consequently, MCTs have a central role in mammalian cell metabolism and are 
critical for the communication between cells as illustrated in Figure 10.  
 
Figure 10. Metabolic pathways involving monocarboxylate transport across the mitochondrial and 
plasma membranes [45]. 
 
Besides being a family of 14 members, only the first four (MCT1-MCT4) have been 
demonstrated experimentally to facilitate the proton-linked transport of 
metabolically important monocarboxylates [46-49]. Since MCT3 is a very 
specialized MCT, being limited to the retinal pigment and choroid plexus epithelia 
[50,51] this introduction will only focus on MCT1, MCT2 and MCT4 isoforms, 
whose function is responsible for the name of this family of transporters [52-56]. 
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Figure 11 shows that MCT1-MCT4 are associated in the same cluster presenting 
high homology. Importantly, this cluster is yet sub-divided in two branches MCT1-2 
and MCT3-4 which correlates with the transported substrate as well as the 
affinities by which those transport is performed. 
 
Figure 11. Human MCT family members’ phylogram, based on amino acid sequence. Boxes 
limited by dots represent the main clusters [57]. 
 
 
1.2.1.1 MCT1 
 
Human MCT1 gene, SLC16A1 is located on chromosome 1 (1p13.2-p12) and 
comprises 5 coding exons. MCT1 functional protein is composed by 500 amino 
acids and has a molecular weight of 53.958 Daltons [58]. 
Among the MCT family, MCT1 isoform is the most well studied and functionally 
characterized member, since it is the only MCT expressed in human erythrocytes. 
Although ubiquitously expressed, MCT1 is especially prominent in heart and red 
muscle, where it is up-regulated in response to increased work, suggesting a 
special role in lactic acid oxidation [59,60]. The wide pattern of expression 
observed for MCT1 may be explained by its substrate affinities that indicate that 
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MCT1, may be involved in both uptake and efflux of monocarboxylates from cells. 
MCT1 transports a variety of substrates including short chain (C2-C5) unbranched 
aliphatic monocarboxylates such as acetate and propionate. Monocarboxylates 
with C2 or C3 substitutions (excluding amino- and amido-) are also transported or 
even preferred (e.g pyruvate, L-lactate, acetoacetate and β- hydroxybutyrate) (35-
37c). The simplest monocarboxylate, formate, is a poor substrate whereas 
bicarbonate; dicarboxylates, tricarboxylates and sulphonates are not transported. 
Also MCT1 is stereoselective for lactate but not for β-hydroxybutyrate. 
MCT1 was also found in mitochondria [61,62] and peroxisomes [63], where it is 
believed to participate in a lactate oxidation complex to maintain organelle redox 
and proper functioning.   
 
 
 
1.2.1.2 MCT2 
 
MCT2 is encoded by the SLC16A7 gene located in chromosome 12 (12q13) and 
comprises 5 coding exons [64]. Although only one transcript is identified, there is 
evidence for alternatively spliced mRNA species in human and rat [51, 63], but no 
evidence of splice variants of the protein. This isoform shares approximately 50% 
sequence identity with MCT1, contains 478 amino acids and has a molecular 
weight of 52,186 Da. The fact that, when both MCT1 and MCT2 are expressed in 
the same tissue, the expression pattern is cell-specific, suggested a distinct 
functional role between these isoforms [64-68]. Subsequent expression of MCT2 
in Xenopus oocytes revealed its unique biochemical feature of facilitating the 
proton-linked transport of especially pyruvate, with a considerable high affinity, 
supporting the previous evidence of an alternative biological role [69].  As so, 
MCT2 also catalysis the proton-linked transport of a range of monocarboxylates, 
but with a considerably higher affinity than MCT1. 
As a higher affinity transporter, MCT2 has also a more restricted expression, being 
adapted to perform the uptake of monocarboxylates into cells. As a result, MCT2 
is found in tissues that use lactate as a respiratory fuel, like brain  or cardiac and 
skeletal muscle, kidney and liver were lactate is the major gluconeogenic substrate 
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[66,67,69,70]. As MCT1, MCT2 is also found in mitochondria [71,72] and 
peroxisomes [63]. 
 
1.2.1.3 MCT4 
 
MCT4 is encoded by the human SLC16A3 gene, which is located in chromosome 
17 (17q25.3), comprises 5 exons and 3 transcripts, with different initiation sites but 
no difference in protein product has been identified. The protein is constituted by 
465 amino acids, corresponding to a molecular weight of 49,469 Da. MCT4 
demonstrates remarkable similarities with MCT1 and in contrast to MCT2 has a 
broader distribution. The principal difference between MCT4 and MCT1 isoforms 
lies on their specific localization and substrate affinities. MCT4 shows a much 
lower affinity for substrates than MCT1 and MCT2. Accordingly, MCT4 is 
predominantly expressed in glycolytic cells such as white muscle and white blood 
cells, suggesting that its physiological function is lactate efflux and in fact, the 
kinetic properties of MCT4 show that this isoform is adapted to the export of 
lactate. This led to the hypothesis that MCT4 might be of particular importance in 
cells that rely on high rates of glycolytic metabolism to meet their energy demands, 
producing high amounts of lactate that need to be rapidly exported, such as 
cancer cells [73].  
 
1.2.1.4 Other MCT isoforms 
 
Other MCT isoforms are being characterized in the last years. SLC18A2 (MCT8) 
gene has been described as a thyroid hormone transporter [74] and mutations in 
this gene have been associated with X linked severe mental retardation and 
neurological dysfunction [76-80]. MCT6 (SLC16A5) transports bumetanide, but 
neither L-lactic acid or L-tryptophan, in a pH- and membrane potential-sensitive 
but in a non-proton gradient-dependent manner [81]. MCT9 (SLC16A9) 
polymorphism was found to be associated with altered serum uric acid [82] 
however MCT9 substrate is still unknown.  Importantly, SLC16A12 (MCT12) has 
been identified as a possible biomarker for colon, prostate and breast carcinoma 
due to gene hypermethylation [83] however the substrate for MCT12 is still 
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unknown, as for the remaining members of the family (MCT5, MCT7, MCT11, 
MCT13 and MCT14). 
Table 1 summarizes the characteristics of the human SLC16 family of transporters 
and Table 2 shows the substrate affinities for the various MCT isoforms in humans 
and rats. 
 
Table 1. The human SLC16 family of transporters [47].  
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Table 2. Comparision of substrate affinities for the various MCT isoforms in human and rat [47]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.2 MCT Regulation 
 
Although the regulatory mechanisms of MCT expression are far from being 
completely understood, evidence indicates that MCTs might be regulated at 
various points up to the functional protein. This includes both transcriptional and 
post-transcriptional level [84-87] that affects protein amounts as well as regulators 
of transporter activity, like chaperone proteins. Hormone regulation has also been 
described for MCTs, as well as regulation by signaling pathways like insulin-like 
growth factor receptor type I (IGF-IR) activation which up- regulates MCT1 [88].  
MCT1 expression is particularly more described than the other isoforms in different 
physiological and pathological conditions. Reports including MCT up-regulation in 
skeletal muscle in response to training [85, 89-96], downregulation after muscle 
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denervation and inflammatory bowel diseases [97,98], changes in MCT expression 
during development [99-103] or substrate induced MCT1 up-regulation [86, 87, 
104] are relatively frequent. However and importantly, regulatory mechanisms vary 
among MCTs isoforms, which allows induction of specific isoforms upon different 
stimuli, adapting cells to different energy demands. 
 
1.2.2.1 Transcriptional Level 
 
The analysis of SLC16A1 5’-flanking region allowed the identification of putative  
binding site sequences for the transcription factors USF, nuclear factor-kappaB 
(NF-kB), activated protein 1 and 2 (AP1 and AP2) and stimulating protein-1 (Sp1). 
USF1 and USF2 have been described as potential repressor proteins for MCT1 
[105] whereas NF-kB pathway has been involved in the butyrate-induced MCT1 
up-regulation [106].  AP2 has been associated to protein kinase C (PKC)-
dependent stimulation of the SLC16A1 promoter [107] . 
Lactate-induced increase in MCT1 has been linked to activation of NF-kB and  
nuclear factor erythroid 2 (NF-E2) pathways, as well as cAMP-response element-
binding protein (CREB) and NF-E2 related factor 2 (Nrf2) transcription factors, the 
last three elements possessing also putative transcription binding sites in the 
SLC16A1 5’-flanking region.  
The co-activators peroxisome proliferator-activated receptor gamma, co-activator 
1 alpha (PGC-1a) [108] and peroxisome proliferator-activated receptor alpha 
(PPAR) [109,110] have been associated with MCT1, but not with MCT2 and 
MCT4 up-regulations. Promoter analyses of MCT1, MCT2 and MCT4 have shown 
that the SLC16A1 promoter contains two peroxisome proliferator-activated 
receptor response elements (PPRE) while SLC16A7 and SLC16A3 each contain 
one PPRE. 
In expression studies, SLC16A1 was also shown to be activated by c-myc and n-
myc proto-oncogenes, while the pro-inflammatory cytokines and TNF-a, have also 
been implicated in the transcriptional control of MCT1, by down-regulating 
SLC16A1 transcription [111-113]. 
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Hypoxic conditions, which are known to induce the glycolytic phenotype, are also 
associated with altered expression of MCTs [114-120]. The first report described a 
tissue-specific change in MCT expression after chronic hypoxia, where MCT1 did 
not change in heart, soleus, or gastrocnemius muscles, and MCT4 increased 
significantly in heart muscle. However, in the plantaris muscle, both MCT1 and 
MCT4 showed a significant decrease after chronic hypoxia [114]. A subsequent 
study suggested that the increase in neuronal, astrocytic and endothelial  MCT1 
expression, observed after permanent occlusion of the left middle cerebral artery, 
is mediated by the hypoxia-inducible factor-1alpha (HIF-1a) [115], the major 
transcriptional  regulator of adaptation to hypoxic stress; however, this view was 
promptly contested by other authors, that showed that only MCT4 promoter was 
activated by hypoxia and that this response was mediated  by HIF-1a [116] . 
Additionally, MCT4, but not MCT1, was shown to be up-regulated by hypoxia  in 
human bladder cancer cells [116] and in trophoblast cells [117], and MCT1 and 
hypoxia were described as being mutually exclusive [118] . In contrast, recent 
evidence shows a hypoxia-mediated increase in both MCT1 and MCT4 and 
decrease in MCT2, with MCT1 and MCT4 change being HIF-1alpha-dependent 
[119]. As so, MCT1 regulation by hypoxia is still very controversial and more 
efforts have to be made to understand MCTs’ regulation by hypoxia. 
 
 
1.2.2.2 Post- Transcriptional Level 
 
The relatively long 3’UTR of SLC16A1 (1.6kb), on which initiation factors and 
regulatory  proteins interact to enhance or repress translation [120], suggests that 
MCT1 expression might also depend on translational regulation in contrast to 
MCT2 and MCT4 which have much shorter 3’UTRs. 
MicroRNAs (miRNAs) are a group of small non-coding RNAs (approximately 22  
nucleotides) that play a critical role in a variety of biological processes, like 
development,  differentiation and apoptosis. Mature miRNAs negatively regulate 
their targets through complementary sequence pairing with the 3' UTR of mRNA 
targets, inducing transcript degradation or translational repression. One of the 
most well characterized miRNAs in mammalian nervous system is miR-124, which 
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has been described to regulate MCT1;  miR-124 regulates SLC16A1 through 
binding to its 3' UTR and MCT1 protein level is reduced after miR-124 transfection 
[121].  
 
1.2.2.3 Transporter Activity Level 
 
Besides being regulated at transcriptional, translational and post-transcriptional 
levels, MCTs are also regulated by interactions with other proteins in order to be 
properly expressed in the cellular membrane. MCT1, and MCT4 are regulated by 
its association with the cell surface glycoprotein CD147 (also known as basigin or 
EMMPRIN), while gp70 (EMBIGIN) is described for translocation of MCT2 to the 
plasma membrane [122].  
CD147 does not exclusively act as a chaperone, in fact, it is a broadly distributed 
plasma membrane glycoprotein, which belongs to the immunoglobulin superfamily. 
CD147 is ubiquitously expressed on the cell surface, with the highest levels found 
in metabolically active cells [123-125].  
Recently, CD44, a widely distributed transmembrane glycoprotein, and its main  
ligand, hyaluronan, were implicated in the regulation of lactate efflux and 
membrane localization of MCTs, in human breast carcinoma cells [126]. This 
protein co-immunoprecipitates with MCT1, MCT4 and CD147 and co-localizes with 
these proteins in the plasma membrane. Figure 12 shows a sum of the most 
significant network found using MetaCore programme for MCT1 (SLC16A1), 
MCT2 (SLC16A7) and MCT4 (SLC16A3). The figure shows interactions among 
SLC16A1, SLC16A7 and SLC16A3 and important proteins already mentioned 
above. Note that these proteins do not act in isolation, but the MetaCore graphic 
shows the essential elements of the network. 
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Figure 12. Top scoring MetaCore network including SLC16A1, SLC16A7 and SLC16A3. This gene network is the best fit found by Metacore to represent 
the relation existent between MCTs and other relevant elements from this database.  
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1.2.2.4 Hormonal Regulation 
 
MCTs regulation by hormones has been firstly described in 2002, as luminal leptin  
was shown to significantly up-regulate MCT1-mediated butyrate uptake, in  Caco2-
BBE cells (human epithelial colorectal adenocarcinoma cells). This increased 
uptake was achieved through two distinct mechanisms: an increase in the 
intracellular pool of MCT1 protein, with no changes in CD147 amounts, and 
translocation of MCT1/CD147 to the apical membrane of Caco2-BBE cell 
monolayers [127]. Shortly after, the hormones thyroid-stimulating hormone (TSH), 
noradrenaline, triiodothryonine (T3) and somatostatin were also described as 
modulators of MCT expression [128-131]. TSH regulates MCT1 protein expression 
in rat thyroid cells, increasing SLC16A1 transcription, and also increases CD147 
protein levels; noradrenaline induces MCT2, but not MCT1 expression, in mouse 
neurons, at the translational level, with the requirement of an yet unknown 
transcriptional step; MCT4, but not MCT1, is induced by T3 in rat skeletal muscle; 
and somatostatin increases MCT1 association with CD147 at the plasma 
membrane, with an increase in the apical membrane levels of MCT1 protein in 
parallel to a decrease in the intracellular MCT1 pool.  
 
1.2.3 MCTs inhibition 
 
As previously mentioned, MCTs are transmembrane proteins exposed to the 
extracellular environment. This feature allows targeting these transporters by 
systemic application of small-molecule inhibitors. Several agents are known to 
inhibit MCT activity, in an isoform-dependent manner, including classical inhibitors 
like  α-cyano-4-hydroxycinnamate (CHC), inhibitors that influence MCT activity in a 
specific manner (eg, MCT1/MCT2 AstraZeneca inhibitors), and compounds that, 
depending on the context of use, have also been described as inhibitors of MCT 
activity like cholesterol synthesis inhibitors (statins) and  non-steroidal anti-
inflammatory drugs. 
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MCT inhibitors fall into three broad categories:  
 
i) Bulky or aromatic monocarboxylates are competitive inhibitors, including 2- 
oxo-4-methylpentanoate, phenyl-pyruvate and derivatives of a-cyanocinnamate  
such as CHC. Also, CHC inhibits the mitochondrial pyruvate transporter as well as 
the anion exchanger 1 (AE1).  
ii) Amphiphilic compounds with widely divergent structures like bioflavonoids  
(e.g. quercetin and phloretin) and anion transport inhibitors such as 5-nitro-2-(3- 
phenyl-propylamino)-benzoate and niflumic acid.  
iii) Stilbenedisulphonates (eg, 4,4’-diisothiocyanostilbene-2,2’-disulphonate (DIDS) 
and 4,4’-dibenzamidostilbene-2,20-disulphonate act as reversible inhibitors of 
MCT1, although with much lower affinity than for AE1. Moreover, miscellaneous 
inhibitors including thiol reagents, such as the organomercurial thiol reagent p-
chloromercuribenzene sulphonate (pCMBS) and amino reagents (eg, pyridoxal 
phosphate and phenylglyoxal) irreversibly inhibit MCTs.  
It is important to emphasize that the affinity of the previous mentioned inhibitors 
depends on the MCT isoform.  
 
1.2.3.1 The classical MCT inhibitor : CHC 
 
Halestrap and colleagues first described an inhibitory effect of CHC in pyruvate 
transport across both the plasma membrane of erythrocytes and also the inner 
membrane of rat liver mitochondria. However, despite being described as an 
inhibitor of pyruvate entry into mitochondria, internalization of CHC into the cells is 
still a matter of debate. 
Recently, Sonveaux et al. [118] demonstrated that the MCT1 activity blockage with 
CHC has antitumor effects: daily CHC delivery in mice did not reveal any overt 
systemic toxicity; Using two experimental mouse models based on MCT1 
expression, Lewis lung carcinoma (with MCT1 plasma membrane expression) and 
hepatocarcinoma (without MCT1 plasma membrane expression), the authors 
observed a tumour growth retardation when targeting MCT1 with CHC and that the 
antitumor efficacy of MCT1 inhibition was restricted to tumour cells expressing 
MCT1 at the plasma membrane. Importantly, inhibiting MCT1 activity with CHC, 
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the authors observed an overall benefit when combining the previous approach 
with radiotherapy [118].  
 
 
1.2.3.2 Specific MCT Inhibitors 
 
It is important to state that neither of the previously mentioned MCT inhibitors is 
either MCT specific or MCT isoform specific. Consequently, the functional role of 
MCTs in cells can only be studied using specific inhibitors.  
Recently, AstraZeneca divulged a new set of small molecular weight compounds 
as potent and selective inhibitors of MCT1 in activated human T cells. Upon T-
lymphocyte activation, MCT1 expression is rapidly unregulated in order to meet 
the demand for lactate efflux arising from increased glycolytic rates. Consequently, 
an effective and highly specific obstruction of MCT1 results in the accumulation of 
lactate within the cells and feedback inhibition of glycolysis. This metabolic 
inhibition results in the inability of T-lymphocytes to sustain the rapid rate of cell 
division during the early immune response. Inhibition of MCT1 with these 
compounds represents a novel mechanism of immunosuppression distinct from 
current therapies [132, 133].  
 
1.2.3.3 Other MCT inhibitors 
 
Diets rich in fruits and vegetables were shown by epidemiological studies to be  
inversely correlated with cancer incidence [134] , playing a pivotal role both in the 
development and prevention of colon cancer.  
Quercetin (3,5,7,3’,4’-pentahydroxylflavone) possesses several beneficial 
biological activities including antioxidant, anti-inflammatory, anti-atherosclerosis 
and antitumor properties [135-137]. Concerning the antitumor properties in CRC 
cancer, Quercetin presents antimetastatic potential against melanoma and 
prostate cancers [138, 139], and suppresses tube formation in human umbilical 
vascular endothelial cells in response to antiangiogenic activity [140]. Entry of 
Quercetin into the cells is described to be via GLUT1, 3 and 4 [141-143]. However, 
it also acts as a high affinity inhibitor of dehydroascorbate and glucose transport 
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through the same transporters. Quercetin is also described as an inhibitor of the 
monocarboxylate transporter isoform 1 (MCT1). In previous studies, it was 
demonstrated that Quercetin acts as reversible noncovalent inhibitor of L-lactate 
transport by tumour cells or red blood cells [144, 145]. More recently, a study 
aiming to clarify the role of flavonoids in the modulation of MCT1-mediated 
transport of hydroxybutyrate in vitro and in vivo demonstrated that Quercetin 
(among others) is an effective inhibitor of MCT1-mediated transport [146].  
 
Lonidamine is a derivative of indazole-3-carboxylic acid, which for a long time, has 
been known to inhibit glycolysis in cancer cells. Although this action was originally 
attributed to hexokinase inhibition [147, 148], further studies revealed that 
lonidamine inhibits lactate efflux from cancer cells  through inhibition of MCT1 and 
MCT4 [149, 150]. Actually, despite a lack of knowledge of its precise mechanism 
of action, lonidamine has been effective in clinical trials against various tumours, 
especially as a sensitizer to other chemotherapies [151].  
 
1.3 Monocarboxylate Transporters in the Context of Cancer 
 
1.3.1 MCTs in human cancer. What is described?  
Regarding cancer research, there are already several evidence for the 
upregulation of MCTs in several solid tumours, such as colorectal carcinomas 
[152], uterine cervix carcinomas [153], glioblastomas, breast carcinomas [154, 
155] and lung tumours [156], pointing to an important role of this transporters in 
the maintenance of these malignancies. The first report on MCT expression in 
human tumor samples described a decrease of MCT1 expression in the colonic 
transition from normality to malignancy [157], which was further supported by a 
larger study [158]. In breast cancer, silencing of SLC16A1 by gene promoter 
hypermethylation was suggested in 4 of 20 breast cancer cases (20 %). In 
contrast, results from our group showed a significant increase of MCT1 
cytoplasmic and plasma membrane expression in breast carcinoma, when 
comparing to normal breast epithelium [154]. MCT4 only showed a significant 
increase in tumor samples for cytoplasm expression, with no differences in plasma 
membrane expression. The literature is also controversial in lung cancer. A study 
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by Koukourakis and collaborators, no expression of MCTs in normal lung was 
found, while expression of MCT1 was found in all tumors examined and both 
MCT2 and MCT4 were also expressed in cancer cells. This study also analyzed 
the possible metabolic cooperation between lung cancer cells and the tumour-
associated stroma, however, tumour associated stroma expressed MCTs weakly 
[15]. In opposition, a recent study by our group showed that normal lung presents 
a high frequency of MCT expression and, in fact, MCT4 is less expressed in tumor 
samples than in normal epithelium.  
MCT expression has also been described in some gynecological tumors like 
cervical and ovarian cancer [159]. In cervical cancer, a significant increase in 
overall and plasma membrane expression of MCT1 and MCT4 was observed. In 
ovarian cancer, staining for MCT1 and MCT4 as well as their chaperone CD147 
was not found in normal ovarian tissues and benign ovarian tissues, while around 
80 % of epithelial ovarian primary and metastatic tumors showed expression of 
these proteins. MCT1 was significantly associated with low grade tumors, high 
FIGO stage, presence of residual tumor, lack of relapse and presence of ascites; 
MCT4 was significantly associated with high grade tumors, high FIGO stage, 
presence of residual tumor, relapse and presence of ascites. Importantly, MCT 
expression was associated with the expression of the multidrug resistance 
markers MDR1 and MRP2. In contrast to what was found in the previous types of 
tumours, neither MCT1 nor MCT4 were found to be up-regulated in gastric 
adenocarcinomas [160]. Actually, MCT4 expression was more frequently observed 
in normal gastric mucosa than in gastric cancer cells and even less frequently 
observed in lymph-node metastasis, indicating a progressive loss of this MCT 
isoform with disease progression. Table 3 shows an overview on MCT1 and MCT4 
expression and the impact on prognosis in different tumour types. 
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Table 3. Overview of MCT1 and MCT4 expression and impact on prognosis in different tumour 
types [57]. 
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Overall, the data available in the literature support the hypothesis of a major role of 
MCTs in the emergence of the hyper-glycolytic and acid-resistant phenotypes, as 
adaptations to the hypoxic microenvironment. The up-regulation of MCTs in the 
plasma membrane of different type of tumors is an adaptive mechanism to allow 
continuous high glycolytic rates, by exporting the accumulating end-product, 
lactate, as well as to counteract acid-induced apoptosis or necrosis. However, it 
was clear that this might not be the case for all tumor types, therefore, in most 
cases there are no functional studies showing the dependence of the tumors on 
MCT expression and activity. As so, additional studies on MCT expression in other 
tumor types, confirmation of the results already published as well as additional 
functional studies are needed to deeply understand the role of MCTs in cancer 
maintenance and aggressiveness and exactly in which cases these transporters 
could be used for therapy.  
 
1.3.2 MCTs as suitable targets for cancer therapy. What is known?  
 
Lately there was an increase in the exploitation of treatments that target tumour 
metabolism, being some of them already in clinical trial phase. Figure 8 shows 
actual and future therapeutic targets of tumour metabolism by targeting metabolic 
enzymes.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Actual and future therapeutic targets (dashed lines) of tumour metabolism by targeting 
metabolic enzymes [161]. 
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Several studies have already shown the in vitro and in vivo effect of targeting 
different MCTs isoforms in human cancers.  
It was demonstrated that MCT inhibition decreases intracellular pH  [162], leads to 
cell death and, importantly, enhances cancer cell radiosensitivity [163]. Results for 
MCT4 show a decrease in cancer cell migration, by mechanisms that also involve 
interaction of MCT4 with β1-integrin [164]. In contrast, another study showed that 
silencing of MCT1 or MCT4 inhibited cancer cell invasion, but did not influence cell 
migration [165]. In vivo models have also been used, where administration of α-
cyano-4-hydroxycinnamic acid (CHC), retarded tumor growth, rendered tumor 
cells sensitive to radiation, induced tumor necrosis and decreased tumor invasion 
[166]. The importance of MCTs for in vivo tumor growth was confirmed by a more 
specific approach, where combined silencing of MCT1 and MCT4 or silencing of 
CD147 significantly reduced glycolytic flux and tumor growth. There are also other 
MCT inhibitors described which are either non-isoform specific (ARC155858 
targets both MCT1 and MCT2 [167] or target other molecules besides MCTs (e.g., 
lonidamine primary target is hexokinase II)) [167,168]. However, these compounds 
have been little explored as lactate transport inhibitors in the cancer context. In 
sum, it seems clear that MCTs represent a suitable target for cancer therapy; 
however, the effect of this inhibition seems highly dependent on the cell type and 
the isoform that is being targeted.  
Figure 14 shows the model for therapeutic targeting of lactate-based metabolic  
symbiosis in tumours. It shows that MCTs inhibition would have a major effect on 
lactate transport, pH balance and tumour homeostasis, by compromising aerobic 
glycolysis and microenvironmental acidosis, as well as, the cell-cell lactate shuttle 
between aerobic and hypoxic cell populations.  
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Figure 14. Model for therapeutic targeting of lactate-based metabolic symbiosis in tumours [118] 
 
Regarding prostate cancer, which is our main focus in this thesis, few studies exist 
reporting the effect of MCTs inhibition in prostate cancer cells. As so, it is 
important to invest in studies evaluating both blocking and the silencing of MCTs in 
prostate cancer in order to reach a conclusion about the effectiveness of this 
therapeutic approach.  
 
 
1.4 Prostate Cancer 
 
1.4.1 Epidemiology of the disease 
Prostate cancer is one of the most prevalent and incident cancers in the male 
population worldwide after lung cancer, and the fifth most common cancer overall. 
In Portugal, prostate cancer is the leading cancer among men with 5,140 
estimated incident cases in 2008 [169, 170]. The patterns of incidence 
and mortality provide a number of interesting leads with peak incidences in the 
United States, Australia and the Scandinavian countries. Incidence rates 
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in Asian countries are generally low, but in recent years have risen proportionately 
more than in western countries. Incidence rates increased dramatically through the 
early 1990s [171].  
In the late 1970s and early 1980s there was a rise in incidence in part, due to 
increased detection with more frequent surgical treatment for benign prostatic 
hyperplasia (BPH), particularly, transurethral resection of the prostate (TURP) 
[172]. Between 1986 and 1992 there was another sharp rise in incidence largely 
due to increasing use of prostate specific antigen (PSA) [173]. A recently 
published study points out an increase of 26% in the incidence of PCa in the 
period between 1986 to 2005 in the United States, which means that more than a 
million additional men were diagnosed with prostate cancer. Besides PSA 
screening programmes, other aspects such as the introduction of better diagnostic 
tools like transrectal ultrasonography (TRUS) –guided biopsy may be partially 
responsible for the increased incidence of prostate cancer in developed countries.  
However, screening practice differences alone are unlikely to explain the nearly 
huge differences in prostate cancer risk between high- and low- risk populations 
[174, 175]. 
Despite prostate cancer's high morbidity, its etiology remains obscure, with the 
only established risk factors being increasing age, race, and a family history. Many 
putative risk factors, including hormones, dietary factors, obesity, physical 
inactivity, occupation, vasectomy, smoking, sexual factors, and genetic 
susceptibility, have been implicated, but the epidemiologic evidence is 
inconclusive. While it is not known whether the risk factors explaining the observed 
patterns are environmental, lifestyle, or genetic, it is likely that a complex interplay 
of these factors is associated with prostate cancer development. 
Concerning mortality, the rates are much less variable than PCa incidence, 
leading to a less accentuated difference between developed and developing 
countries.  With the introduction of PSA a slight increase in mortality rates was 
observed  but this increase was verified both in high and low risk countries [176]. 
The reasons for this time trends in mortality rates are still controversial but the 
introduction of the PSA screening was in certain way responsible for the 
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increasing rates due to miscertification of cause of death among men diagnosed 
with latent tumours, however it may also play a role in decreasing rates because of 
an earlier diagnosis of most of the cases.   
Early detection in prostate cancer is crucial since only organ-confined disease is 
amenable to curative treatment whereas patients with advanced disease can only 
be palliated. Although there are some available tools frequently used for PCa 
detection, their performance is sub-optimal due to non-satisfactory sensitivity and 
specificity rates. In this context, new biomarkers are urgently needed, not only to 
early detection but also as ancillary tools for diagnosis, which is still based on 
histopathological evaluation of biopsy specimens.  
1.4.2 Prostate Cancer Diagnosis 
Usually, men with PSA levels of 4.0 ng/mL or greater are candidates to perform a 
prostatic core needle biopsy [177]. This cut off value for the PSA test is still 
controversial because PSA level screening produces false-negative or false-
positive results that can lead men without disease to be submitted to unnecessary 
additional testing [177, 178]. Importantly, PSA levels screening are not acceptable 
diagnostic tools for PCa in routine clinical practice because they lack adequate 
sensitivity and specificity. Regardless the utility of diagnosis aid-tools, the only way 
to access diagnosis of prostate cancer is by histopathological analysis of prostatic 
tissue obtained from biopsy or prostatectomy specimens. It is crucial to perform a 
proper histopathological evaluation of the tissue collected from the patient in order 
to determine which are the best treatment options available for each patient 
because the combination of this evaluation results with other parameters, such as 
serum PSA levels, in nomograms do have prognostic impact [179]. Biopsy 
techniques have been improved in order to reduce morbidity and increase the rate 
and accuracy of detection in the first biopsy, although the optimal number of cores 
that must be collected is still a matter of debate [178].  
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1.4.2.1 Histophatological evaluation. The Gleason score system for prostate 
cancer grading 
The Gleason grading system was firstly described in 1996 and it is presently, with 
some modifications, the most commonly used method for prostate cancer grading. 
Because the Gleason score (GS) is directly correlated with PCa prognosis, its 
accurate evaluation is critical to the natural history of the disease or the risk of 
recurrence following radical prostatectomy or radiotherapy [180]. 
The system is based on the evaluation of the glandular architectural patterns of 
the tumour tissue, recognizing five different grades that range from good to poor 
grade of differentiation. Because prostate adenocarcinomas are heterogeneous, 
more than one of the five patterns defined by Gleason might be present in the 
same tumour. To incorporate this heterogeneity in tumour grading, the Gleason 
score (GS) was developed, resulting from the sum of two most predominant 
cancer pattern (grades) in a sample. GS varies from 2 (1+1) to 10 (5+5) (Figure 
15).   
Figure 15. Updated Gleason score for histological grading 
of prostate tumours [181] . 
Pattern 1- Closely packed small, uniform glands. 
Pattern 2- More stroma between the glands that are round 
or oval with smooth ends and may minimally invade non-
neoplastic tissue. 
Pattern 3- Irregular size glands with angular shape and 
more infiltrative margins. 
                                                       Pattern 4- Fused, cribiform or poorly defined glands. 
                                                       Pattern 5- Only occasional gland formation. 
 
1.4.2.2 Clinical and Pathological Staging 
 
Another aspect that helps to predict the progression of PCa is the staging which 
comprises information about the extension of the disease (local, regional or 
systemic) and it is widely classified using the UICC (International Union against 
Cancer) Tumour Node Metastasis (TNM) system (Table 4). In this classification, T 
represents the extent of the primary tumour, N the lymph node status and M to 
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distant metastasis. The clinical stage is based on the evaluation of the patient by 
digital rectal exam (DRE), transrectal ultrasonography (TRUS), and, possibly, 
magnetic resonance imaging (MRI) [178,182,183] . Further information can be 
provided by biopsy histopathological evaluation and serum PSA levels [188]. 
Alternatively, pathological stage is determined after surgical removal of the 
prostate through adequate analysis of the prostatectomy specimen, and it predicts 
disease recurrence much more accurately [183]. There are several independent 
prognostic factors included in staging that are important to guide clinical decisions 
concerning the treatment options. These are extra-prostatic tumour invasion, 
seminal vesicles involvement, lymph node metastasis and distant metastasis. 
These features have been combined in nomograms with other prognostic factors, 
such as preoperative serum PSA levels, GS in the prostatectomy specimen and 
surgical margins status in an attempt to refine the prediction of prognosis 
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Table 4. Overview of the UICC TNM/pTNM staging system for prostate cancer 
[182] . 
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1.4.3 A brief overview in the treatment options for prostatic adenocarcinoma  
 
TNM classification, GS, preoperative serum PSA levels, patients age, life 
expectancy and quality of life are parameters that must be taken into account 
previous to therapeutic decision in order to classify the patient according to risk of 
disease progression and mortality [184]. After taking into account the evaluation of 
these features several therapeutic options are available for PCa patients, namely  
watchful waiting (active surveillance), surgery, radiotherapy, and hormone therapy 
[179].  
Watchful waiting is a viable option for some prostate cancers because the natural 
history of this disease is often long and many patients diagnosed with early stage 
PCa are more prone to die with, rather than from, the disease [185]. So, for men 
with less than 10 years of life expectancy and with low-risk tumours (i.e., tumours 
highly to moderately differentiated – GS < 7, stage T1c to T2a and serum PSA 
equal to or less than 10ng/mL)  active surveillance should be offered  as well as 
for patients with relevant comorbidities or with asymptomatic metastatic disease 
and a strong wish to avoid treatment-related side effects, it is also an option [184]. 
Radical prostatectomy is the standard curative treatment for prostate cancer. Of all 
the treatments available, it has a survival advantage when compared to active 
surveillance. The improvement of surgical techniques resulted in high cure rates 
with reduced morbidities (e.g. erectile dysfunction or urinary incontinence), which 
are frequent in patients submitted to radical prostatectomy [179]. 
Hormone therapy is used in men with advanced prostate cancer to shrink the 
cancer and slow the growth of tumors. In men with early-stage prostate cancer, 
hormone therapy may be used to shrink tumors before radiation therapy. This can 
make it more likely that radiation therapy will be successful. Hormone therapy is 
sometimes used after surgery or radiation therapy to slow the growth of any 
cancer cells left behind.  Blocking the supply of hormones may cause cancer cells 
to die or to grow more slowly. Hormone therapy options include medications that 
stop your body from producing testosterone as luteinizing hormone-releasing 
hormone (LH-RH) agonists prevent the testicles from receiving messages to make 
testosterone. Drugs typically used in this type of hormone therapy include 
leuprolide (Lupron, Eligard), goserelin (Zoladex), triptorelin (Trelstar) and histrelin 
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(Vantas), medications that block testosterone from reaching cancer cells. 
Medications known as anti-androgens prevent testosterone from reaching cancer 
cells. Examples include bicalutamide (Casodex), flutamide, and nilutamide 
(Nilandron). These drugs typically are given along with an LH-RH agonist or given 
before taking an LH-RH agonist. Also surgery to remove the testicles 
(orchiectomy) reduces testosterone levels in the body. Orchiectomy in lowering 
testosterone levels is similar to that of hormone therapy medications, but 
orchiectomy may lower testosterone levels more quickly. 
However, most tumours submitted to androgen deprivation acquire a hormone-
refractory phenotype. For these patients the only available options are 
conventional chemotherapy, whose effectiveness is still limited [178, 184]. More 
recently, hormonal therapy has been evaluated as adjuvant therapy in combination 
with radical prostatectomy or radiotherapy, but only for the latter case it shows an 
improvement in survival [179].  
Several major clinical challenges are associated with this conventional paradigm 
for prostate cancer diagnosis and treatment, as so, the major aim is still the search 
for new prospects to answer old challenges.  
 
1.4.4   What is known about prostate cancer metabolism? 
 
As it was mentioned above most malignancies have increased glycolysis for 
energy requirement of rapid cell proliferation, which is the basis for tumor imaging 
through glucose analog 2-deoxy-2-fluoro-D-glucose (FDG) with positron emission 
tomography. Indeed there are studies reporting the presence of hypoxia in PCa, 
pointing to the presence of a glycolytic phenotype in prostate cancer cells [186-
189]. In contrast, other authors have shown that one of the significant 
characteristics of prostate cancer is slow glycolysis and low FDG activity. Also, 
another  study revealed that GLUT1 mRNA and protein were only very weakly 
expressed in human prostate cancer tissue, which is considered to account for low 
FDG activity of prostate cancer [190]. As so, FDG-PET has not been very helpful 
in staging or detection of recurrence of prostate cancer because of low glycolysis. 
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Clinical trials showed that FDG accumulation does not even correlate with 
increasing grade or stage of the tumor and there is a significant overlap in FDG 
uptake between benign prostate hyperplasia and prostate cancer [191, 192]. Other 
positron-emitting radiotracers, such as 18F-choline, 11C-choline, 11C-acetate 
and 18F-fluorodihydrotestosterone have recently been suggested as putative 
imaging agents for the detection of prostate tumors [191-195]. Clinical evaluation 
of these radiotracers is presently underway and the role of PET scanning in 
prostate cancer is still evolving [190,196,197].  
Studies suggest that increased citrate oxidation is a significant metabolic 
characteristic for the bioenergy requirement in prostate cancer. The normal human 
prostate gland, has the function of producing, accumulating and secrete high 
levels of citrate [198, 199] and in contrast to normal glands and benign 
hyperplasia, prostate cancer is characterized by a low levels of citrate (Figure 16). 
Based on bioenergetics of prostate epithelial cell metabolism, Costello and 
Franklin proposed the “bioenergetic theory of prostate malignancy”: the 
transformation of a citrate-producing sane epithelial cell to a malignant citrate-
oxidating cell that would result in a more efficient energy-generating system. 
Additionally, the authors suggest that in order to meet the energetic requirements 
of malignant cells, the metabolic transformation into citrate oxidation must be an 
early event in preparation for the progression of malignancy and preceded the 
histopathologic identification of malignant cells [198, 200, 201] . In fact, changes of 
citrate levels in the form of choline/citrate for detection and localization of prostate 
cancer is a basis of magnetic resonance spectroscopy (MRS) for in situ detection 
of prostate cancer [202, 203]. Recent studies showed that activity of mitochondrial 
(m)-aconitase, the first reaction before citrate oxidation, is significantly higher in 
prostate cancer compared to normal prostate, which drives the utilization of citrate 
as energy source [198].  
In order to maintain this net citrate production, continuous availability of 
oxaloacetate and acetyl-CoA is required for continuous citrate synthesis. Acetyl-
coenzyme A is the only molecule consumed in citrate cycle and its continuous 
availability is crucial for driving citrate oxidation. Recent studies also suggested 
that to meet the bioenergetic requirement for rapid cell proliferation in prostate 
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cancer there are changes of fatty acid metabolism that provide both ATP and 
acetyl-CoA to make the acceleration of citrate oxidation possible.  
 
 
 
 
 
 
 
 
 
Figure 16. Concept of pathogenesis of prostate malignancy. The high zinc levels in mitochondria 
inhibit m-aconitase resulting in the inability to oxidize citrate and the accumulation of citrate. As the 
cellular zink levels are decreased in the premalignant cell, citrate oxidation occurs with the 
concurrent increased production of ATP. The malignant cell is now metabolically and energetically 
capable of proceeding with its malignant process (From [202]). 
 
Although some evidence supports a crucial role of fatty acid-related metabolism in 
the pathogenesis and progression of prostate malignancy [204, 205],  the reports 
are scarce with low number of clinical samples and with no information regarding 
the clinico-pathological significance of these alterations; as so, PCa metabolism is 
still largely unknown and consequently which metabolic pathway represents the 
most appropriate target for metabolic inhibition in PCa is still controversial.  
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CHAPTER  2. DIAGNOSTIC/PROGNOSTIC VALUE OF MCTs AND 
CHAPERONES EXPRESSION IN PROSTATE CANCER   
Role of MCTs in Prostate Carcinoma Pértega-Gomes N. 
 
56 
 
  
Role of MCTs in Prostate Carcinoma Pértega-Gomes N. 
 
57 
 
 
2.1. CHAPTER OVERVIEW  
Most malignancies rely on glycolysis for rapid proliferation even in the presence of 
oxygen, leading to production of large amounts of acids, mainly lactic acid. 
Consequently, the high glycolytic phenotype induces an acidic tumour 
environment, which is associated with the increase of several malignant features 
including cellular migration, invasion and metastization. 
The evidence for the upregulation of MCTs in several solid tumours, such as 
colorectal carcinomas, uterine cervix carcinomas, melanomas, breast carcinomas 
and lung tumours was already described,  however, in prostate carcinoma, the role 
of MCTs was unknown. 
In this chapter, MCT1, MCT2, MCT4, Gp70 and CD147 expressions were 
evaluated in a comprehensive series including 171 patients, who performed 
radical prostatectomy and 14 patients who performed cystoprostatectomy. 
Samples and clinico-pathological data were retrieved and organized into tissue 
microarray (TMAs) blocks. Protein expression was evaluated by 
immunohistochemistry in neoplastic (n = 171), adjacent non-neoplastic tissues (n 
= 135), PIN lesions (n = 40) and normal prostatic tissue (n = 14). Protein 
expression was correlated with patients' clinicopathologic characteristics. 
In this study, already published in an international scientific periodical with 
referees, a significant increase of MCT2 and MCT4 expressions was observed. 
Importantly, while MCT1 was observed at the plasma membrane, MCT2 and 
MCT4 were in the cytoplasm.  Also, analysis of MCT  expression in regard to the 
clinico-pathological parameters showed associations of MCT4 and CD147  
expression and reliable markers of poor prognosis such as PSA levels, Gleason 
score and pT stage, as well as with perineural invasion and biochemical 
recurrence. Additionally, we also verified an involvement of MCTs 1 and 4 with 
proteins associated with drug resistance and cancer progression, which could 
imply that MCTs are involved in these two processes. 
. 
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2.2 PUBLISHED RESULTS 
The results presented in this chapter were: 
 
(i) Published as an original article in an international peer reviewed journal 
 
Pértega-Gomes N, Vizcaíno JR, Miranda-Gonçalves V, Pinheiro C, Silva J, 
Pereira H, Monteiro P, Henrique RM, Reis RM, Lopes C, Baltazar F. 
“Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated 
with poor prognosis in prostate cancer.” BMC Cancer 2011 Jul 25;11:312. 
(HIGHLY ACCESSED) (Citations ISI: 19). 
 
(ii) Selected for publication as an abstract in international scientific journals 
Pértega-Gomes N, Vizcaíno JR, Lopes C, Baltazar F. “Monocarboxylate 
transporters as targets for cancer therapy”. Abstract published in conference 
proceedings Microsc Microanal 2009;15: 17-18, Supplement S3.  
Pértega-Gomes N, Vizcaíno JR, Lopes C, Baltazar F. “Monocarboxylate 
transporters 2 and 4 are upregulated in prostate carcinoma”. Abstract published 
in conference proceedings Virchows Arch 2009,455:233, Supplement: Suppl. 1. 
 
(iii) Presented as oral communication in the following national scientific 
meeting: 
Pértega-Gomes N, Vizcaíno JR, Lopes C, Baltazar F. “Characterization of 
Monocarboxylate transporters in prostate cancer”. XIII Workshop of Urological 
Oncology, 2010, Espinho, Portugal.  
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(iv) Presented as poster in the following international scientific meetings: 
Pértega-Gomes N, Vizcaíno JR, Lopes C, Baltazar F. et al. “Assessment of 
monocarboxylate transporters 1 and 4, CD147, CD44 and MDRI could help to 
predict biochemical recurrence in prostate cancer”. XX Porto Cancer Meeting, 
IPATIMUP, Porto, Portugal, 2011. 
 
(v)  Were recognized with the following prizes/awards: 
Pértega-Gomes N, Vizcaíno JR, Lopes C and Baltazar F. “Characterization of 
Monocarboxylate transporters in prostate cancer”. Honorable Mention for best 
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2.2.1 Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is 
associated with poor prognosis in Prostate Cancer 
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CHAPTER 3. MONOCARBOXYLATE TRANSPORTER 2 (MCT2) IN PROSTATE 
CANCER: EXPRESSION, FUNCTION AND EXPLOITATION AS A BIOMARKER 
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3.1 CHAPTER OVERVIEW 
 
Besides the challenges in the prognostic and therapeutic field in PCa, the 
diagnosis of the disease can also represent a challenge.  
The diagnosis of prostate cancer can sometimes present a diagnostic challenge 
for pathologists, since, prostate carcinoma can mimic benign prostate glands and 
the architectural or cytologic clues to a diagnosis of carcinoma may not always be 
seen in small foci of suspicious glands. Also, diagnosis of prostate cancer can be 
difficult in needle biopsies or in minimal residual cancer of radical prostatectomies, 
presenting one of the major challenges in surgical pathology. Therefore, it would 
be of great importance and usefulness to have molecular markers with high 
sensitivity and specificity for prostate carcinoma. 
In the previous chapter we observed an evident increase in MCT2 expression in 
the cytoplasm of PCa cells comparing to non-neoplastic tissue. This observation 
lead us to explore more deeply MCT2 as a putative prostate cancer biomarker. In 
this chapter we present results where we compare the sensitivity and specificity of 
MCT2 and AMACR (an already established prostate cancer biomarker) in 
recognizing prostate cancer, by analyzing the immunohistochemical expression of 
both markers in a large series of prostate samples, including normal prostate, non-
neoplastic tissue, PIN lesions and tumour tissues and assess its clinico-
pathological value. Also, we aimed to measure the sensitivity and specificity of 
combining MCT2 and AMACR as positive markers together with the negative 
markers p63 and 34βE12, using tissue microarrays (TMAs), which recapitulate the 
small problematic foci of glandular proliferation that are generally encountered in 
prostatic biopsy specimens. Also, we aimed to study the subcellular localization of 
MCT2 in prostate cancer cells across malignant transformation. 
Our study revealed that MCT2 as well as AMACR is consistently expressed in 
prostate cancer regardless Gleason score and in combination with AMACR and 
p63 or 34βE12 will help to improve the diagnosis of prostate carcinoma. 
Importantly, we found MCT2 interacting with PEX19 and co-localizing with 
peroxisomal clusters, being this co-localization more evident from the non-
malignant model PNT1a to the malignant 22RV1, suggesting once again a role for 
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MCT2 in prostate malignant transformation, more than in the aggressiveness and 
progression of the disease.  
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3.2 PUBLISHED RESULTS 
The results presented in this chapter were: 
 
(i)  Published as an original article in an international peer reviewed journal 
Pértega-Gomes N. Vizcaíno JR, Gouveia C., Jerónimo C., Henrique RM., Lopes 
C. and Baltazar F. et al “Monocarboxylate transporter 2 (MCT2) as putative 
biomarker in prostate cancer. The Prostate. 2012 Nov 28. doi: 
10.1002/pros.22620. 
(ii) Submitted for publication as an original article in an international peer 
reviewed journal 
Pértega-Gomes N, Valença I, Vizcaíno JR, Ribeiro D., Baltazar F. “Localization of 
MCT2 at peroxisomes is associated with malignant transformation in prostate 
cancer”2013. 
(iii) Presented as oral communication in the following national scientific 
meeting: 
Pértega-Gomes N, Vizcaino JR, Gouveia C, Lopes C and Baltazar F. 2010 
“Comparative study between MCT2 and AMACR in prostate cancer diagnosis” 
Work presented at Pathology Department Day at Centro Hospitalar do Porto 
(CHP). 
(iv) Presented as poster in the following national scientific meeting: 
Pértega-Gomes N, Vizcaino JR, Gouveia C, Lopes C and Baltazar F. 2010. 
“Monocarboxylate transporter 2 as a putative prostate cancer biomarker” at XIX 
Porto Cancer Meeting at IPATIMUP, Porto, Portugal.  
 
(v) Were recognized with the following prizes/awards: 
Pértega-Gomes N., Vizcaino JR., Gouveia C., Lopes C. and Baltazar F. 2010 
“Comparative study between MCT2 and AMACR in prostate cancer diagnosis” 1st 
Prize for best poster and oral communication (Dr.Mário Costa Award) in  
Laboratorial Pathology meeting of CHP-Hospital de Sto.António, Porto, 
Portugal. 
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3.2.1 Monocarboxylate transporter 2 (MCT2) as a putative biomarker in 
prostate cancer. 
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3.3.1 Localization of MCT2 at peroxisomes is associated with malignant 
transformation in prostate cancer
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Abstract 
Metabolic adaptation is now considered a new hallmark of cancer, in which cancer 
cells exhibit high rates of glucose consumption and consequent lactate production. 
A previous study of MCTs expression in prostate cancer drew attention to the 
isoform 2 (MCT2) which was shown to be clearly expressed in prostate malignant 
glands, but at the cytoplasm of cancer cells, suggesting the presence of this 
transporter in an organelle membrane. Lately, MCT2 was suggested as a putative 
biomarker for prostate cancer, however, the localization and the role of MCT2 in 
prostate cancer cells still totally unknown. 
In this work we aimed to explore more deeply MCT2 and its chaperone gp70 in 
prostate cancer cells using different in vitro models of disease progression and 
aggressiveness. Also, we provide a more detailed description on the localization of 
the other MCT isoforms at cellular level in prostate cancer cells.  
We observed for the first time the presence of MCT2 in the peroxisomal 
membrane of prostate cancer cells and importantly, we described the interaction 
between MCT2 and the peroxisomal biogenesis factor 19 (PEX 19), as its 
chaperone, in alternative to the well-described gp70 in other tissues. We also 
observed that MCT2 localization in peroxisomes changes according to the disease 
stage. Curiously, we also observed that the distribution of MCT1 and MCT4 
appeared to change across the different models of malignant transformation, 
suggesting alternative roles for these transporters in other cellular pathways rather 
than glycolysis.   
All together, our results show for the first time MCT2 in prostate cancer 
peroxisomes interacting with PEX19, and highlight the importance of this organelle 
in prostate cancer disease. Also it was observed that MCT2 levels seemed to be 
associated with β-oxidation levels, paving the pathway for look at these 
transporters as targets for different metabolic pathways, different than glycolysis in 
cancer cells. 
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Introduction 
 
Prostate cancer (PCa) is the second most common malignancy in men, which 
sometimes involves a challenging diagnosis [1]. Several proteins, among which 
alpha-methylacyl-CoA racemase (AMACR) was identified as possible new PCa 
biomarker [2,3].  
Monocarboxylate transporters (MCTs) are proteins that facilitate the 
transmembrane transport of monocarboxylates, such as pyruvate and lactate [4]. 
In glycolytic tumors, they promote the efflux of lactic acid, being important players 
in the maintenance of the tumor intracellular pH, avoiding the routing to apoptosis 
and providing the favorable microenvironment conditions for invasion.  Our recent 
studies point out to a consistent overexpression of MCT2 and MCT4 in prostate 
cancer [5,6]. Importantly, although MCT2 expression was not correlated with 
clinico-pathological parameters, this protein caught our attention due to its strong 
staining in tumour cells in contrast to a mainly negative staining in benign glands. 
We have also reported that, in terms of sensitivity and specificity to detect 
malignant glands, MCT2 staining was comparable to alpha-methylacyl-
CoA racemase (AMACR), an already established biomarker in prostate cancer, 
raising the hypothesis that MCT2 could have an important role in prostate cancer 
disease [6]. However, so far, the precise localization and role of MCT2 in PCa is 
still unknown.  
The unique biochemical feature of human MCT2 among the other MCTs is its high 
affinity for the transport of pyruvate, being a primary pyruvate transporter in man 
[7]. MCT2 is encoded by the SLC16A7 gene located in chromosome 12 (12q13) 
and comprises 5 coding exons. Although only one transcript is identified, there is 
evidence for alternatively spliced mRNA species in human and rat but no evidence 
of splice variants of the protein. This isoform shares approximately 50% sequence 
identity with MCT1, contains 478 amino acids and has a molecular weight of 52 
KDa.[7]. As a higher affinity transporter, MCT2 has also a more restricted 
expression. Being adapted to perform the uptake of monocarboxylates into cells, 
MCT2 is found in tissues that use lactate as a respiratory fuel, such as brain, 
cardiac and skeletal muscle, kidney and liver, where lactate is the major 
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gluconeogenic substrate [8-13]. As MCT1, MCT2 is also found in mitochondria 
[12,13] and was also localized at peroxisomes in non-tumor liver fractions [14]. 
The presence of MCTs in mitochondria is justified by the need of a pyruvate carrier 
that plays a central role in carbohydrate and fat metabolism. In contrast, the 
presence of MCT1 and MCT2 in peroxisomes was justified as being involved in a 
lactate-pyruvate shuttle system present in the membrane of this organelle. This 
shuttle was suggested to be involved in the oxidation of NADH generated by β-
oxidation, being crucial for the maintenance of peroxisomal viability and 
consequent β-oxidation rates [14]. This was the only study regarding this matter 
and it was not done in the cancer context, as so, little is known about lactate 
shuttles as well as the involvement of peroxisomal alterations in cancer.  
In this work we aimed to unraveling MCT2 intracellular localization and expression 
across prostate malignant transformation using different models of disease 
progression in order to infer about the importance of this isoform in prostate 
cancer disease. Also, the other MCT isoforms where assessed in order to 
characterize in more detail their intracellular distribution. 
 
 
Material and methods 
Cell culture 
In this study we have used different prostate cell lines, PNT1A (non-malignant), 
22Rv1 (localized tumor), LNCaP (lymph node metastasis) and PC3 (bone 
metastasis). Cells were seeded in RPMI-1640 (Gibco, Invitrogen, USA) 
supplemented with 10% of fetal bovine serum (FBS) (PAA Laboratories GmbH, 
Cölbe, Germany), 1% of antibiotic (penicillin/streptomycin) (PAA Laboratories 
GmbH, Cölbe, Germany) and incubated at 37⁰C in an atmosphere containing 5% 
CO2.  
 Immunofluorescence and microscopy techniques 
Immunofluorescence was performed in order to identify the intracellular 
localization of MCT1, MCT2 (sc-14926, Santa Cruz Biotechnology, Santa Cruz, 
CA), MCT4 and its chaperones CD147 and gp70. Fluorophores TRITC (Jackson 
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ImmunoResearch) and Alexa 488 (Invitrogen, Life Technologies, Grand Island, 
NY, USA) were used as secondary antibodies. 
Immunofluorescence was performed in cells seeded on glass cover slips that were 
fixed after 24h with 4 % paraformaldehyde in PBS, pH 7.4 for 20 min. Afterwards 
cells were permeabilized with 0.2 % Triton X-100 for 10 min, blocked with 1 % 
BSA solution for 10 min and incubated with primary (MCT2, catalase, PEX19 and 
Gp70) and secondary antibodies [TRITC (Jackson ImmunoResearch) and Alexa 
488 (Invitrogen, Life Technologies, Grand Island, NY, USA)] for 1 h each.  
Between each step, cells were extensively rinsed 3 times with PBS, pH 7.4. Lastly, 
cells were stained with and mounted in slides using Mowiol 4-88 containing n-
propylgallate. Images were obtained using a Zeiss LSM 510 Meta Confocal setup 
(Carl Zeiss, Oberkochen, Germany) equipped with a plan-Apochromat 100×/1.4 oil 
objective. 
 
Western Blot 
Cells were lysed with specific lysis buffer (25 mM Tris-HCl, pH 8.0, 50 mM sodium 
chloride, 0.5% sodium deoxycholate, 0.5% Triton X-100 and a protease-inhibitor 
mix). To improve protein extraction, samples were passed 20 times through a 26-
gauge syringe needle and incubated on a rotary mixer at for 30 min at 4⁰C. After 
cleared by centrifugation (13300 rpm, 15 min) protein concentrations were 
determined by the Bradford assay (BioRad, Hercules, CA, USA). Blots were 
incubated with specific primary antibodies, MCT2, gp70, PEX14, Catalase, 
ACOX1, ACOX3 and PEX19. The antibodies were detected by a horseradish 
peroxidase-linked secondary antibody using an enhanced chemiluminescence 
system (GE Healthcare, Waukesha, WI, USA). 
 
Immunoprecipitation 
22Rv1 cells were transfected with Pex19-YFP using Turbofect in vitro transfection 
kit (Fermentas, USA), according to the manufacturer’s instructions. For 
immunoprecipitation of Pex19-YFP we used GFP trap_M (Chromotek). 
Transfection with a plasmid containing GFP was used as negative control. After 
48h of transfection cell pellets were incubated lysis buffer (10mM Tris-HCl, pH 7.5, 
150mMNaCl, 0.5mM EDTA, 0.5%NP-40 and a protease-inhibitor mix). The lysate 
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was cleared by centrifugation (13300 rpm, 15 min) and diluted with dilution buffer 
(10mM Tris-HCl, pH 7.5, 150mM NaCl, 0.5mM EDTA and a protease-inhibitor 
mix). Protein concentrations were determined by the Bradford assay (BioRad, 
Hercules, CA, USA). Ice-cold dilution buffer was used to equilibrate beads and cell 
lysates were incubated for 2 h at 4°C on a rotary mixer. Beads were washed 3 
times with dilution buffer and resuspended in 3x SDS-sample buffer and boiled for 
10 min to elute bound proteins. Immunoprecipitated samples were separated by 
running in a 12.5% SDS-polyacrylamide gel. 
 
Results 
MCT2 was detected in the peroxisomes of prostate cancer cells at different 
levels within disease progression 
The intracellular localization of MCT2 was accessed in different models of prostate 
cancer disease progression. As McClelland et al have shown a peroxisomal 
localization of MCT2 in non-tumor liver fractions, we firstly tested whether this 
protein would also be present in this organelle in prostate cancer cells. To that 
end, we have performed immunolocalization of MCT2 together with the 
peroxisomal marker catalase in different prostate cell lines: PNT1A (non-
malignant), 22Rv1 (localized tumor), LNCaP (lymph node metastasis) and PC3 
(bone metastasis). Our results demonstrate that, while no co-localization was 
observed between MCT2 and the peroxisomal marker in PNT1A, this protein is 
localized at peroxisomes in all the malignant cell lines (Fig 1). We have, though, 
observed that the localization level varied across the different models. In 22Rv1 
cells, MCT2 was mainly found in the peroxisomes with a minor portion spread 
throughout the cytoplasm as small aggregates (Fig1 d-f). However, the ratio of 
peroxisomal MCT2/cytoplasm MCT2 decreased with disease progression, 
culminating with almost no MCT2 in the peroxisomes in PC3 cells (Fig1 j-l). 
Surprisingly, the amount of MCT2 at peroxisomes appears to correlate with a 
change on the organelle’s morphology. In fact, in cells where no MCT2 was 
present in peroxisomes (PNT1A), this organelle exhibits a regular phenotype (Fig 
1A: a-c). Curiously, in 22Rv1 cells (where MCT2 was mainly observed in 
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peroxisomes) this organelle appears somewhat in clusters (Fig. 1A: d-f) LNCaP 
cells exhibit more distributed rounder peroxisomes with only a few clusters 
(Fig.1A: g-i). In PC3, the highly metastatic model, peroxisomes appear similar to 
the ones of the non-malignant cells PNT1A (Fig 1A: j-l). Strikingly, the expression 
level of MCT2 increases from non-tumor (PNT1A) to localized malignant cells 
(22Rv1), correlating to its change in localization from cytoplasmic to peroxisomal 
(Fig 1B). This increase in expression was also observed for Pex14 (a peroxisomal 
membrane protein) (Fig 1C), suggesting an increase in peroxisomal membrane 
surface/number that accompanies the malignant transformation. 
MCT2 travels to the peroxisomal membranes trough PEX19 
The quick movement of monocarboxylates across the membranes is imperative for 
cellular metabolism. These proteins are thought to require chaperones  such as 
CD147 in the case of MCT1 and MCT4, or gp70 in the case of MCT2, for 
appropriate expression and activity in the plasma membrane [15]. Since MCT2 
was the only isoform found to localize in peroxisomes in prostate cancer cells, we 
aimed at unraveling its targeting mechanism to this organelle. A previous study 
was unable to find gp70 expression in human prostate samples that exhibited 
MCT2 expression [5]. However, our studies with confocal microscopy allowed us 
to observe some, although scarce, gp70 distributed in the cytoplasm without any 
co-localization with peroxisomal markers (Fig 2 a-l). Hence, the protein that 
behaves as chaperone for MCT2 transport to peroxisomes in prostate cells is still 
unknown. 
As Pex19 is the main protein responsible for the transport of peroxisomal 
membrane proteins to this organelle, we tested whether this protein could act as a 
chaperone for MCT2 in these cells. Being 22RV1 the cell line where MCT2 was 
mainly present at peroxisomes, it was the chosen model to study the possible 
interaction between MCT2 and PEX19.  Immunoprecipitation experiments have 
shown, indeed, an interaction between MCT2 and PEX19  (Fig 3). These results 
suggest a highjack of the peroxisomal transport mechanism by the prostate cancer 
cells. 
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The presence of MCT2 at peroxisomes seems to be related with an increase 
in the rates of peroxisomal β-oxidation 
McClelland et al observed a decrease in β-oxidation upon MCTs inhibition, 
suggesting that the presence of MCT2 at peroxisomes of non-malignant liver cells 
would be essential for the maintenance of peroxisomal viability and consequently 
β-oxidation rates. Hence, we hypothesized that the increase of MCT2 expression 
from non-malignant prostate cells (PNT1A) to localized prostate tumor cells 
(22RV1) could be related with an increase in peroxisomal β-oxidation. In fact, we 
observed an increase in the expression levels of ACOX1 and ACOX-3, central 
proteins in the β-oxidation pathway (Fig 4). These results interestingly suggest 
that, indeed, the increase in MCT2 expression levels as well as its presence at 
peroxisomes, are related to an increase in β-oxidation levels which may be crucial 
for malignant transformation. 
The distribution of other MCTs isoforms and CD147 at intracellular level 
suggests an additional role for these proteins in prostate cancer 
MCT1, MCT4 and CD147 expressions were also evaluated in this study. MCT1 
showed a strong nuclear expression in PNT1a and 22RV1, decreasing for LNCaP 
and PC3, where this transporter was mainly found in the cytoplasm and plasma 
membrane (Fig.5).  MCT4 however was shown to be present in the cytoplasm of 
the less tumorigenic cell lines 22RV1 and LNCaP in contrast to the highly 
metastatic PC3 where it was clearly present at the plasma membrane (Fig.6). 
CD147 was present in the plasma membrane, cytoplasm and nuclear envelope 
(Fig.7).  
Interestingly, some co-localization between MCTs 1 and 4 and peroxisomes, was 
also verified, however it was less evident than for MCT2. 
 
Discussion 
It is now widely accepted that the transport of lactate and pyruvate is mediated by 
a family of H+/monocarboxylate transporters (MCTs) known for their specificity to 
transport short chain monocarboxylates. They form an integral part of proposed 
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shuttles that transport lactate between cells (cell–cell lactate shuttle) and within 
cells (intracellular lactate shuttle). 
A previous study of MCTs expression in prostate cancer drew attention to MCT2 
that was shown to be clearly expressed in prostate malignant glands but at the 
cytoplasm, suggesting the involvement of this transporter in an organelle 
membrane [6], however there were no studies describing the existence of MCT2 in 
the organelles of prostate cancer cells.  
It is known, that once in the mitochondrial matrix, lactate and pyruvate undergo 
further breakdown making it difficult to infer their respective roles in the shuttling of 
reducing equivalents to the electron transport chain. Peroxisomes, on the other 
hand, lack the enzymes to catabolize monocarboxylates and although they are 
known to contain LDH [16], they are not known to contain any other glycolytic or 
any tricarboxylic acid cycle enzymes. One of the many functions of liver 
peroxisomes is the β-oxidation of long branched-chain fatty acids and for the 
maintenance of these reactions inside the peroxisome, a redox shuttle system 
exist across the peroxisomal membrane to reoxidize NADH. It is essential for the 
continuous functioning of peroxisomes that proper intra-organelle reduction–
oxidation (redox) balance is maintained that ensures the reoxidation of NADH 
produced by β-oxidation and the continuous breakdown of fatty acids. Redox 
balance in many organelles is maintained in part by substrate shuttles. This would 
entail a shuttle system in peroxisomes that neither generates products nor 
consumes any substrates. 
McClelland et al proposed that a redox shuttle system that consists of a substrate 
cycle between lactate and pyruvate, as so, to play their role in peroxisomal redox 
balance, pyruvate and lactate must be transported across the peroxisomal 
membrane [14]. 
In the present study we describe for the first time that MCT2 is present in human 
prostate peroxisomes and a possible explanation for how these MCT2 ends up in 
the peroxisomal membrane was given by the evident interaction of MCT2 with 
PEX19 which might act as chaperone. The absence of glycolysis in this organelle 
strongly suggests that this shuttle serves to maintain redox balance and not 
glycolysis or some other metabolic function. Consequently, we point out the 
importance of peroxisomes in prostate cancer cells that as it was observed a clear 
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change their morphology across prostate malignant transformation, which provides 
further evidence for the dynamic nature of the peroxisomes across disease 
progression. Importantly, the frequency of peroxisomal clusters and the co-
localization with MCT2 that was mainly observed in the transition from the benign 
model (PNT1a) to the malignant model (22RV1), point to the involvement of these 
alterations in tumour initiation. Finally, the possibility of having MCT1 and MCT4 in 
the peroxisomal membrane, however less evident than for MCT2, corroborates the 
hypothesis of alternative roles for these transporters in metabolic pathways 
different from glycolysis in the present cells. However, further studies are needed 
to understand the role of these MCT isoforms in prostate peroxisomes.  
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 A) Immunohistochemical images of different human prostate cell lines PNT1a (Figure 1a-
c), 22RV1(Figure 1d-f), LNCaP (Figure 1g-i) and PC3 (Figure 1j-l). Superposition of signals from 
probes for MCT2 (green), and Catalase (red) shows clear colocalization (yellow in the peroxisomes 
of prostate cancer cells).  
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Figure 1 B) Western blot analysis showing the levels of MCT2 in the different prostate cell line 
models.  
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Figure 1 C) Western blot analysis, showing the expression levels of the peroxisomal protein PEX-
14 in the different in vitro models of prostate cancer progression (PNT1a, 22RV1, LNCaP and 
PC3). 
 
 
 
 
 
 
 
 
 
 
 
Role of MCTs in Prostate Carcinoma Pértega-Gomes N. 
 
102 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Immunohistochemical images of different human prostate cell lines PNT1a (Figure 2a-c), 
22RV1 (Figure 2D-F), LNCaP (Figure 2G-I) and PC3 (Figure 2J-L). Superposition of signals from 
probes for gp70 (green), and Catalase (red) showed clear colocalization (yellow in the peroxisomes 
of prostate cancer cells). 
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Figure 3.  Interaction of MCT2 with PEX19 using co-immunoprecipitation (Co-IP) and Western blot 
in 22RV1 cell line. 
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Figure 4.  Western blot analysis, showing the expression levels of the proteins ACOX-1 (A) and 
ACOX-3 (B) involved in the peroxisomal branched chain fatty acid, in the different in vitro models of 
prostate cancer progression (PNT1a, 22RV1, LNCaP and PC3). 
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Figure 5. Immunohistochemical images of different human prostate cell lines PNT1a (Figure 7A) 
,22RV1(Figure 7B), LNCaP (Figure 7C) and PC3 (Figure 7D) showing probes for MCT1 
(green). A clear presence of MCT1 in both plasma membrane and nucleus was observed in 
all the models studied.  
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Figure 6. Immunohistochemical images of different human prostate cell lines PNT1a (A-C), 
22RV1(D-F), LNCaP (G-I) and PC3 (J-L). Superposition of signals from probes for MCT4 (green), 
and Catalase (red) showed clear colocalization (D, yellow in the peroxisomes of prostate cancer 
cells). 
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Figure 7.  Immunohistochemical images of different human prostate cell lines PNT1a (a-c), 
22RV1(d-f), LNCaP (g-i) and PC3 (j-l) showing probes for CD147 (green). A clear presence of 
CD147 in both plasma membrane and perinuclear envelope was observed in all the models 
studied.  
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CHAPTER  4. EXPLOTATION OF METABOLIC ALTERATIONS AS 
TARGETS FOR THERAPY 
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4.1  CHAPTER OVERVIEW  
We firstly described overexpression of MCT2 and MCT4 in PCa tissues when 
compared to the normal counterparts, however, the role of MCTs in PCa 
metabolism is still largely unknown. The presence of MCT4 in the cytoplasm of 
prostate cancer cells instead of plasma membrane together with the expression 
of MCT1 in both non-malignant and malignant glands, suggested that prostate 
cells may not firstly rely on glycolytic metabolism as the majority of tumours. 
This verification turned this work even more challenging in an attempt to 
contextualize the role of different MCTs isoforms across prostate malignant 
transformation and progression. 
As stated before, it remains unclear what is the primary energetic pathway in 
PCa and therefore which metabolic pathway represents the most appropriate 
target for metabolic inhibition in PCa. There are studies reporting the presence 
of hypoxia in PCa, pointing to the presence of a glycolytic phenotype, however 
other studies report that PCa is characterized by low rates of glycolysis and a 
low FDG activity on PET imaging. This fact raises the hypothesis that if glucose 
consumption is not elevated in PCa, alternative metabolic pathways must 
provide the energy needed for cancer cell proliferation and growth. Some 
evidence support a crucial role of fatty acid-related metabolism in the 
pathogenesis and progression of prostate malignancy. However, the reports are 
scarce with low number of clinical samples and with no information regarding 
the clinico-pathological significance of these alterations; as so, PCa metabolism 
is still largely unknown.  
This chapter includes results already submitted for publication, showing the 
expression pattern of several metabolic-related proteins involved in glycolytic 
and fatty acid oxidation pathways from benign prostate to metastatic PCa, 
investigating the prognostic impact of their expression. Also, using different in 
vitro models of disease progression we tested how the inhibition of these 
pathways affect the different models of prostate cancer cells in order to 
establish a rationale for metabolic phenotypes across prostate malignant 
transformation and progression. 
Overall, the results presented here indicate a switch from less aggressive tumor 
to glycolytic metabolism in the highly aggressive and metastatic prostate tumor 
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and underscores the plasticity of bioenergetic pathways in prostate cancer cells 
which might have crucial implications at prognostic and therapeutic level.  
 
4.2 PUBLISHED RESULTS 
The results presented in this chapter were: 
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meeting: 
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4.3.1 Metabolic heterogeneity in prostate cancer is linked to disease 
progression and aggressiveness  
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Abstract  
Metabolic adaptation is now considered a new hallmark of cancer, in which 
cancer cells exhibit high rates of glucose consumption with consequent lactate 
production. However, the dominant energetic pathway as well as the clinical 
impact of altered cellular metabolism in prostate cancer is still largely unknown.  
In an attempt to understand the metabolic alterations during prostate cancer 
progression and how these alterations could represent suitable tools for 
prostate cancer at diagnostic, prognostic and therapeutic level, we studied the 
expression of several key metabolic-related proteins in 480 human prostate 
samples and using in vitro models we assessed metabolic changes associated 
with malignant transformation/progression and how their manipulation affects 
different models of prostate cancer cells. Also we provided an insight into the 
cell mitochondrial features and used publicly available genome-wide expression 
profiling datasets to assess the expression of the genes that codify metabolic-
related proteins during prostate cancer progression. 
This study provides evidence for increased glycolytic phenotype mainly in the 
advanced stages of prostate cancer, and its correlation with poor prognosis 
whereas the localized tumour showed more consistently upregulation of 
proteins involved in peroxisomal branched-chain fatty acid oxidation without any 
association with clinic-pathological data. Importantly, experiments using in vitro 
models showed that cell lines derived from distant metastasis are more 
glycolytic, sensitive to glycolytic inhibitors and with lower energy efficiency at 
the mitochondrial level. 
This is the most comprehensive study reporting the metabolic differences 
across prostate malignant transformation and correlating the metabolic 
heterogeneity of prostate cancer cells with unfavorable prognosis, showing that 
metabolic changes have a strong potential to be explored as diagnostic, 
prognostic and therapeutic tools in prostate cancer.  
Keywords: prostate cancer, cancer metabolism, monocarboxylate transporters, 
glycolytic metabolism, fatty acid oxidation, metabolic switch. 
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Introduction 
Metabolic changes during malignant transformation have been noted for many 
years. Warburg firstly reported that cancer cells preferentially rely on glycolysis 
for energy production, even in the presence of oxygen, leading to the production 
of high levels of lactate [1]. Our group described for the first time the expression 
and the involvement of monocarboxylate transporters (MCTs), proteins which 
facilitate the transmembrane transport of lactate, as promising targets in cancer 
therapy in several human cancers [2-7].  Regarding prostate cancer, although 
we have found some important correlations with prognostic parameters, the 
presence of MCT1 in both tumour cells and non-malignant tissues as well as 
the absence of MCT4 at the plasma membrane of cancer cells lead us to 
hypothesize that prostate cancer might rely less than most tumours on aerobic 
glycolysis [8-9]. However, it remains unclear what is the primary energetic 
pathway in PCa and therefore which metabolic pathway represents the most 
appropriate target for metabolic inhibition in PCa. There are studies reporting 
the presence of hypoxia in PCa, pointing to the presence of a glycolytic 
phenotype [10-13], however, other studies report that PCa is characterized by 
low rates of glycolysis and a low 2-fluoro-2-deoxy-D-glucose FDG activity on 
positron emission tomography PET imaging [14-16]. This fact raises the 
hypothesis that if glucose consumption is not elevated in PCa, alternative 
metabolic pathways must provide the energy needed for cancer cell proliferation 
and growth. Some evidence supports a crucial role of fatty acid-related 
metabolism in the pathogenesis and progression of prostate malignancy [17-
18]. However, the reports are scarce with low number of clinical samples and 
with no information regarding the clinico-pathological significance of these 
alterations, thus, PCa metabolism is still largely unknown.  
Making use of a large human casuistic and different in vitro models of prostate 
cancer disease progression, this study aims to address for the first time the 
metabolic heterogeneity across prostate malignant transformation and 
progression and infer about its significance in the clinical context. 
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Materials and methods 
Patients’ samples 
Prostate tissues were obtained from 480 patients with a median age of 64 years 
old, who performed radical prostatectomy between 1993 and 2010. Samples, 
including 203 non-neoplastic, 176 high-grade prostatic intraepithelial neoplasia 
(PIN) and 480 neoplastic tissues, and clinico-pathological data were retrieved 
from the files of the Department of Pathology, Centro Hospitalar do Porto and 
organized into tissue microarray blocks (TMAs), as previously described [9]. 
Benign samples were obtained from 12 patients undergoing radical 
cystoprostatectomy for transitional cell carcinoma of the bladder and 8 
metastatic PCa cases were obtained from clinical biopsy samples. The present 
study was previously approved by Local Ethical Review Committees. 
Cell lines and cell culture 
Four human prostate cell lines representing different relevant features of 
prostatic adenocarcinoma were used. The selected cells lines were 22RV1, 
LNCaP, PC3 and DU145 (ATCC-American Type Culture Collection, MD, USA). 
Cell lines were grown in RPMI-1640 cell culture medium supplemented with 
10% Fetal Bovine Serum (FBS) (GIBCO®, Invitrogen,Carlsbad, CA) and 1% 
Penicillin-Streptomycin (P-S) (GIBCO®, Invitrogen, Carlsbad, CA).  
Immunohistochemistry (IHC)  
The expression of lactate transporters (MCT1, 2 and 4), glucose transporters 
(GLUT-1 and GLUT-12), proteins involved in the glycolytic cascade (HKII, 
LDHV and PDKI), cellular biomarkers of hypoxia (CAIX and HIF-1alpha) and 
finally proteins involved in fatty acid oxidation (AMACR, ACOX-3 and DBP) 
were analyzed in prostate tissue samples using a combined score system 
previously described [2-7].  IHC technique was performed according to the 
detailed information given in Table 1 and IHC evaluation was performed blindly 
by two independent observers that assessed the intensity and the extention of 
the staining as previously described [9].  
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Heat map construction 
A heat map representing the staining of each protein for each clinical case was 
constructed using R statistical software for statistical computing and graphics.  
Western blot 
Western blot analysis was performed for protein expression in all cell lines. 
Details are given in Table 2. 
 
Drugs 
Thioridazine (TZ), phytanic acid (PA) and oxamic acid (OA) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in dimethyl sulfoxide 
(DMSO; Sigma-Aldrich) to prepare the stock solutions from which the working 
solutions were made.  
 
Metabolism assay (extracellular glucose and lactate measurements) 
Cells were plated in 24-well plates until confluence. A concentration of 40mM of 
OA (according to the concentration range used in the literature) was used. 
Glucose consumption and lactate production were quantified before and after 
treatment using commercial kits (Roche and Spinreact, respectively), as 
previously described [2]. 
 
Cell viability assay 
The effect of treatment with TZ on cell biomass was determined at 24, 48 and 
72 hours by MTS assay (Sigma-Aldrich), according to the manufacturer’s 
recommendations. IC50 values (i.e., TZ concentration that corresponds to 50% 
of cell growth inhibition) were estimated from 3 independent experiments. All 
values were normalized for untreated controls. MTS assay was also used to 
assess the effects of increasing concentrations of phytanic acid in cell lines.   
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Ultrastructural studies 
 
Fresh human tissues were harvested from patients undergoing radical 
prostatectomy at Portuguese Institute of Oncology, Porto. Prostate tissue was 
reseated from peripheral zone and immediately fixed following surgical removal. 
LNCaP and PC3 cells were also used for electron microscopy analysis. 
Samples were processed and observed using a transmission electron 
microscope as previously described [19]. 
 
Mitochondrial DNA (mtDNA) characterization, haplogroup affiliation and 
cell respiratory efficiency 
The complete mtDNA of the cell lines LNCaP and PC3 was amplified in 32 
overlapping fragment with primers and PCR conditions (described in Table S1, 
Supplementary data). The same primers were used to directly sequence both 
strands of the fragments using the Promegafmol® DNA Cycle sequencing 
System and the Usb Thermo Sequence Radiolabelled Terminator Cycle 
Sequencing Kits. Sequences were aligned and compared with the revised  
Cambridge Reference Sequence [20] , by using the software BioEdit. The 
diversity observed in each cell line was automatically classified by using the 
software mtDNA-GeneSyn [21], and a pathogenicity score [22] was inferred for 
the non-synonymous polymorphisms based upon the list provided in Pereira et 
al. [23] for all possible non-synonymous mutations which can occur in the 
human mtDNA by point mutations. Haplotypes were also assigned to 
haplogroups by using the software Haplogrep [24], which also indicates the 
polymorphisms that are potentially private and the ones shared by ancestry.  
 
Analysis of cell respiratory efficiency 
The activity of the mitochondrial complex I (NADH:ubiquinone oxidoreductase) 
was evaluated enzymatically by using the Complex I Enzyme Activity Microplate 
Assay Kit (ab109721) (Abcam®), in cells cultures with 70-80% confluence, 
according to the manufacturer’s instructions. The global cellular ATP levels 
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were quantified using Luminescent ATP Detection Assay Kit (ab113849, 
Abcam).  
 
Public genome-wide expression profiling datasets analysis 
The Varambally dataset (Varambally et al., 2005) containing the expression 
profiling data from 16 microdisected samples representing benign prostate, 
primary tumour and metastases, was used. Also, the Glinsky dataset (Glinsky et 
al., 2004), which contains expression data and clinical follow-up for 79 prostate 
cancer patients, was used to determine if the expression of any of the proteins 
studied correlate with clinical outcome. 
Statistical analysis 
Data from human tissue samples were analyzed with SPSS statistical software 
(version 18.0; SPSS) using the Pearson’s χ² test, with the threshold for 
significance being p ≤ 0.05. For the in vitro studies, the GraphPad prism 5 
software was used, with the Student’s t-test, considering significant values to be 
p ≤ 0.05. 
 
 
Results  
The expression profile of key metabolic-related proteins changes across 
prostate malignant transformation 
Figure 1 shows the final staining score presented by each protein studied in 
each case of benign prostate tissue (BT), non-neoplastic prostate tissue (NT), 
PIN lesions (PIN), tumour tissue (TT) and metastatic tumour tissue (MT). The 
colours distinguish the cases in which the final score was negative (0), weak 
(1), moderate (2) and strong (3). We observed important changes in the 
expression of all the metabolic-related proteins studied from benign and/or 
adjacent non-neoplastic prostate tissue to PIN lesions and to primary tumour. 
Firstly, an increase in MCT2, MCT4, GLUT-1, GLUT-12, LDHV, PDK1, CAIX, 
AMACR, ACOX-3 and DBP expressions was observed from BT and NT to TT. 
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Interestingly, an evident increase was verified from BT or NN to PIN and TT for 
proteins involved in fatty acid oxidation whereas proteins involved in the 
glycolytic pathway, namely MCT4, LDHV, HKII, PDKI and CAIX were positive in 
all metastatic samples. The specific percentage of positive cases for each 
protein in different tissues, as well as, the differences between proteins 
expressions among the different tissue types can be seen in the Supplementary 
data (Figure S1 and Table S2, respectively). Table 3 shows the association 
between CD147 and CD44 expressions and both MCT1 and MCT4, suggesting 
a role for these glycoproteins as chaperones for the lactate transporters.  
MCT4, GLUT-1 and CAIX change their cellular localization from prostate 
primary tumour to metastasis  
Figure 2 (2A, 2B and 2C) shows representative immunohistochemical reactions 
for all proteins in BT, PIN, TT and MT and Table 4 summarizes the sub-cellular 
localization of each protein studied in the different human tissues. In general, 
normal prostate epithelium was either negative or weakly positive for most of 
metabolic proteins studied with the exception for MCT1 CD147 and CD44, 
whereas PIN lesions and adenocarcinomas showed intense staining in most 
cases. The most strikingly findings were obtained for MCT4 (Fig 2A, C1-C4), 
GLUT-1 (Fig 2B,A1-A4) and CAIX (Fig. 2B, F1-F4) that change their subcellular 
localization to the plasma membrane TT to MT. Also HIF1-alpha appeared in 
the nucleus of the cells in metastatic samples (Fig. 2B, G4).  
Proteins involved in glycolytic metabolism associate with poor prognosis 
parameters 
The detailed associations between the expression of the metabolic proteins and 
clinico-pathological data is presented in Table 5. In general, we observed that 
various proteins involved in the glycolytic pathway associate with important 
prognostic parameters in contrast to proteins involved in fatty acid oxidation.  
Importantly, MCT4 and CAIX, were the only ones showing an association with 
patients’ survival status (p=0.040 and p=0.039, respectively). Kaplan-Meier 
curves and Log Rank test showed no associations between disease-free 
survival and proteins expression, however, although not statistically significant, 
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there was a decrease in the survival of patients with tumours expressing CAIX, 
(data not shown). 
 
Different in vitro models of PCa progression exhibit different protein 
expression and glycolytic metabolism profiles 
Since the main differences observed across malignant progression in human 
samples were related to proteins involved in the glycolytic metabolism, in Figure 
3 we show the expression profile of these proteins in different in vitro models of 
disease progression. Interestingly, MCT4 and HIF-1alpha were only proteins 
detected in DU145 and PC3 cell lines. Also, GLUT-1, LDHV and CAIX showed 
evident higher levels in PC3 cell line. Interestingly, the ICC results for the 
different cell line models show that MCT4 and GLUT-1 only appeared evidently 
expressed at the plasma membrane in the highly metastatic models, such as 
PC3, in contrast to the low tumorigenic cell line LNCaP (Figure 3B). 
Finally, a clear distinct metabolic behaviour between the low tumorigenic 22RV1 
and LNCaP and the high tumorigenic PC3 and DU145 models was observed. 
PC3 and DU145 exhibited higher levels of glucose consumption (Figure 3C) 
and lactate production (Figure 3D) when compared to 22RV1 and LNCaP cells. 
Prostate cancer cells exhibited different sensitivities to inhibition of 
glycolysis and fatty acid oxidation  
Based in the idea that different models of disease progression exhibited a 
different metabolic behaviour, we aimed to study the effect of glycolysis and 
fatty acid oxidation inhibition in the different models. 
Oxamic acid (OA), an inhibitor of lactic dehydrogenase (LDH), was used to infer 
how the glycolytic metabolism in the different models is affected after inhibition 
of lactic acid production. Figure 4 shows the glucose consumption and lactate 
production of prostate cell lines after the treatment with OA. It is possible to 
observe that both parameters showed a significant decrease in 22RV1, PC3 
and DU145 cell lines. In contrast, LNCaP cell line metabolism was less affected 
by OA treatment.  
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The phenothiazine drug, thioridazine (TZ), described as a selective inhibitor of 
peroxisomal β-oxidation, was also used in our cell line models.  As observed in 
Figure 5A, the IC50 values show that 22RV1 and LNCaP cell lines are more 
sensitive to TZ effect, especially at 72 h treatment. Accordingly, when we 
supplemented the culture media with phytanic acid (PA), a long branched chain 
fatty acid, to stimulate fatty acid oxidation, a decrease in PC3 and DU145 cell 
viability was observed, but not in 22RV1 and LNCaP that maintain their viability 
with increasing concentrations of PA, even after 48 hours of exposure (Figure 
5B). 
Ultrastructural differences are evident among the different prostate cancer 
cell models 
So far, we have observed that differences at the expression levels of proteins 
involved in glycolytic and fatty acid metabolism as well as in cells metabolic 
behavior are evident across malignant transformation. As so, we also aimed to 
verify if such differences might be also reflected at the ultrastructural level of the 
cells. Figure 6 shows electron micrographs of LNCaP (Figure 6A), PC3 (Figure 
6B) and two different human samples of prostate cancer (Figure 6C and 6D). It 
was possible to observe that either in LNCaP cells or the human samples 
(Figure 6A, 6C and 6D, respectively), cells are packed with lipid bodies. Also, in 
what concerns mitochondria morphology, these images clearly show differences 
in terms of subcellular features of localized prostate tumours and the low 
tumorigenic model LNCaP cell line in comparison with the cells derived from 
highly metastatic tumours (PC3).  
Analysis of the mitochondrial genome reflects a decrease in the efficiency 
of PC3 cell lines through increased expression of UCP2 protein 
A complete mtDNA sequencing of the cell lines LNCaP and PC3 (as two clearly 
distinct models of disease progression) was performed (Table 6). The results 
showed that the LNCaP haplotype can be affiliated in the European haplogroup 
H26c, displaying the coding private mutation in ND5 gene at position 13227, 
which is a synonymous polymorphism. The PC3 haplotype belongs to another 
European haplogroup, denominated U5a1c, and bears two non synonymous 
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recent mutations: in gene ND4, at position 11120, leading to the F121L amino 
acid replacement, which has a MutPred pathogenicity score of 0.423; and in 
gene ND5, at position 13802, conducting to the amino acid replacement T489M, 
having a MutPred pathogenicity score of 0.6. We have inferred, on the basis of 
a large population dataset of mtDNA genomes, that the value of MutPred score 
dividing pathogenic mutations from tolerated mutations is around 0.7. The two 
nonsynonymous mutations in PC3 cell line have scores below this threshold, 
but we do not know yet if the mutations can contribute additively to a 
phenotype. As both PC3 mutations are located in proteins of the Complex I, if 
they have some functional impairment in the oxidative phosphorylation it will be 
upon this complex.  
Investigating Complex I activity in prostate cell lines we observed that in 
contrast with we were expecting, PC3 cells show increased Complex I activity 
(Figure 7A). However the increased Complex I activity in PC3 cells was not 
reflected in global cellular ATP levels (Figure 7B). These results suggest that 
the proton electrochemical gradient across the inner mitochondrial membrane 
(IMM) is being dissipated and not used for ATP production. In fact, investigating 
the expression levels of the mitochondrial uncoupling protein 2 (UCP2), we 
verified that it is significantly higher in PC3 cells, both using β-actin protein 
(p=0.02) as total protein loading, and the translocase of outer mitochondrial 
membrane 20 homolog (TOMM20) (p<0.01), as a mitochondrial protein loading 
indicating that PC3 cells exhibit few mitochondria and thus confirming our 
ultrastructural data (Figure 8A-D).  
 
Public genome-wide expression profiling datasets show association of 
metabolic-related proteins with disease progression 
By making use of publicly available genome-wide expression profiling datasets, 
we immediately observed that the mRNA levels of genes involved in the 
glycolytic pathway were higher in metastatic tumours compared to localized 
tumours (Figure 9A), whereas, the differences in the expression patterns 
observed for the genes involved in the fatty acid oxidation pathway were less 
striking (Figure 9B). 
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Interestingly, looking to the genes that codify for lactate transporter proteins, 
only the mRNA levels of SLC16A3, the gene that codifies for MCT4, the isoform 
responsible for lactate extrusion were higher in metastatic compared to 
localized tumours (Figure 9E). Finally, the Glinsky dataset showed again 
SLC16A3 gene being associated with the time to biochemical recurrence after 
surgery (Figure 10). 
 
Discussion  
While numerous studies have investigated the involvement of altered cellular 
metabolism in various tumours, little is known about the metabolic alterations 
during prostate cancer progression.  
Costello et al. [25,26] described the transformation of a citrate-producing 
epithelial cell to a malignant citrate oxidizing, which must be an early event for 
malignancy and progression. Additionally, Shan Zha et al described the 
selective upregulation of peroxisomal branched chain fatty acid β-oxidation 
pathway in prostate cancer [17], which might represent a good source of acetyl-
CoA for Krebs cycle, and later, Ranasinghe W. et al [27] linked hypoxia with 
aggressiveness and metastasis in prostate cancer. However, whether the 
expression of proteins involved in cellular energetic metabolism is altered during 
prostate malignant transformation and progression, as well as, the significance 
of their expression is largely unknown.  
 In this study, we found a consistent overexpression of proteins involved in 
peroxisomal branched chain fatty acid oxidation in prostate cancer as well as in 
PIN lesions in contrast to benign glands, suggesting a possible etiological role 
of this pathway in malignant transformation. In the other hand, the expression of 
proteins involved in the glycolytic pathway showed association with reliable 
predictors of poor prognosis such as tumour stage (pT), Gleason score and 
biochemical recurrence, suggesting a role in disease progression. 
Accordingly, our in vitro studies showed that different models of disease 
progression exhibited different metabolic profiles. The cell lines derived from 
distant metastasis are more glycolytic and strongly express MCT4 and GLUT-1 
Role of MCTs in Prostate Carcinoma Pértega-Gomes N. 
 
128 
 
at the plasma membrane, two major players in the glucose uptake and lactate 
extrusion essential for the proper function of the glycolytic pathway. Importantly, 
a change in the subcellular localization of these proteins from localized tumour 
to metastatic tumour was verified, with MCT4, GLUT1 and CAIX being present 
at the plasma membrane only in metastatic samples, suggesting an obvious link 
between the plasma membrane function of these proteins and the aggressive 
stage of the tumour.  
Using inhibitors of the different pathways we were able to support the idea that 
different metabolic pathways are active according to the disease stage of the 
tumour. Thus, targeting fatty acid oxidation seems to be more relevant in an 
early stage in contrast to the glycolytic pathway, which will produce more effects 
in an advanced stage of the disease. 
Additionally, differences were also evident at the organelle content level, 
between low and high tumorigenic models, which led us to investigate the idea 
of a less energetically efficient respiration of the highly tumorigenic models. In 
fact, we found an false increase in Complex I activity in PC3 cells masked by 
the overexpression of UCP2 protein, justifying a coupling defect in oxidative 
phosphorylation in these cells. Interestingly, a coupling defect in oxidative 
phosphorylation was also described in mitochondrion-rich (Hürthle or oncocytic) 
tumours of the thyroid [28-31].  
Finally, publicity dataset supported our main findings showing that the 
expression of genes involved in fatty acid oxidation mostly changed from benign 
samples to localized tumour specimens, suggesting a clear role mainly in 
prostate malignant transformation rather than progression, whereas, genes 
involved in the glycolytic metabolism are aberrantly expressed mainly in the 
metastatic samples, being more compatible with a role in prostate cancer 
progression and aggressiveness, and drawing attention in this case for 
SLC16A3 gene that codifies MCT4 as a  predictive marker of disease 
progression and aggressiveness. This data also indicates that prostate cancer 
does not fit in the traditional model of a metabolic switch to glycolysis from non 
malignant to malignant cells but instead this metabolic switch is more likely to 
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be involved in the advanced stage of the disease and importantly prior to 
pathologic transformation, exhibiting a predictive value. 
To the best of our knowledge, this is the largest study investigating the role of 
key metabolic-related proteins in relation to outcome of radical treatment to 
localized prostate cancer, putting together a large variety of clinical samples 
and in vitro models, demonstrating the metabolic heterogeneity of prostate 
cancer and its significance as diagnostic, prognostic and therapeutic tool in 
prostate cancer disease.  
  
Acknowledgements 
NPG and SS received fellowships from the Portuguese Foundation for Science 
and Technology (FCT), refs. SFRH/BD/61027/2009 and PTDC/SAU-
MET/113415/2009 respectively. This work was supported by the FCT grant ref. 
PTDC/SAU-MET/113415/2009, under the scope of “Programa Operacional 
Tematico Factores de Competitividade” (COMPETE) of “Quadro Comunitario 
de Apoio III” and co-financed by Fundo Comunitario Europeu FEDER. This 
work was partially supported by the project (PIC/IC/83037/2007). Further 
funding was obtained from the project ‘Microenvironment, metabolism and 
cancer’ based at IPATIMUP and partially supported by Programa Operacional 
Regional do Norte (ON.2—O Novo Norte), under the Quadro de Referência 
Estratégico Nacional (QREN), and through the Fundo Europeu de 
Desenvolvimento Regional (FEDER). IPATIMUP and ICVS/3Bs are associate 
laboratories of the Portuguese Ministry of Science, Technology and Higher 
Education and is partially supported by the FCT. 
 
 
 
 
Role of MCTs in Prostate Carcinoma Pértega-Gomes N. 
 
130 
 
Statement of author contributions 
All authors meet the criteria for authorship in that they have participated in the 
conception, execution or interpretation of at least part of the publication in their 
field of expertise. 
All authors read and approved the final manuscript. 
 
  
Role of MCTs in Prostate Carcinoma Pértega-Gomes N. 
 
131 
 
References 
1. Warburg, O., F. Wind, and E. Negelein, The Metabolism of Tumors in the Body. J Gen 
Physiol, 1927. 8(6): p. 519-30. 
2. Miranda-Goncalves, V., et al., Monocarboxylate transporters (MCTs) in gliomas: 
expression and exploitation as therapeutic targets. Neuro Oncol, 2013. 15(2): p. 172-88. 
3. Pinheiro, C., et al., Role of monocarboxylate transporters in human cancers: state of the 
art. J Bioenerg Biomembr, 2012. 44(1): p. 127-39. 
4. Pinheiro, C., et al., Expression of monocarboxylate transporters 1, 2, and 4 in human 
tumours and their association with CD147 and CD44. J Biomed Biotechnol, 2010. 2010: 
p. 427694. 
5. Pinheiro, C., et al., Monocarboxylate transporters 1 and 4 are associated with CD147 in 
cervical carcinoma. Dis Markers, 2009. 26(3): p. 97-103. 
6. Pinheiro, C., et al., Increasing expression of monocarboxylate transporters 1 and 4 
along progression to invasive cervical carcinoma. Int J Gynecol Pathol, 2008. 27(4): p. 
568-74. 
7. Pinheiro, C., et al., Increased expression of monocarboxylate transporters 1, 2, and 4 in 
colorectal carcinomas. Virchows Arch, 2008. 452(2): p. 139-46. 
8. Pertega-Gomes, N., et al., Monocarboxylate transporter 2 (MCT2) as putative 
biomarker in prostate cancer. Prostate, 2012. 
9. Pertega-Gomes, N., et al., Monocarboxylate transporter 4 (MCT4) and CD147 
overexpression is associated with poor prognosis in prostate cancer. BMC Cancer, 
2011. 11: p. 312. 
10. Higgins, L.H., et al., Hypoxia and the metabolic phenotype of prostate cancer cells. 
Biochim Biophys Acta, 2009. 1787(12): p. 1433-43. 
11. Effert, P., et al., Expression of glucose transporter 1 (Glut-1) in cell lines and clinical 
specimens from human prostate adenocarcinoma. Anticancer Res, 2004. 24(5A): p. 
3057-63. 
12. Stewart, G.D., et al., Analysis of hypoxia-associated gene expression in prostate 
cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason 
score. Oncol Rep, 2008. 20(6): p. 1561-7. 
13. Vaz, C.V., et al., Androgen-responsive and nonresponsive prostate cancer cells present 
a distinct glycolytic metabolism profile. Int J Biochem Cell Biol, 2012. 44(11): p. 2077-
84. 
14. Giovacchini, G., et al., [11C]choline positron emission tomography/computerized 
tomography to restage prostate cancer cases with biochemical failure after radical 
prostatectomy and no disease evidence on conventional imaging. J Urol, 2010. 184(3): 
p. 938-43. 
15. Hong, H., et al., Positron emission tomography imaging of prostate cancer. Amino 
Acids, 2010. 39(1): p. 11-27. 
Role of MCTs in Prostate Carcinoma Pértega-Gomes N. 
 
132 
 
16. Farsad, M., et al., Positron-emission tomography in imaging and staging prostate 
cancer. Cancer Biomark, 2008. 4(4-5): p. 277-84. 
17. Zha, S., et al., Peroxisomal branched chain fatty acid beta-oxidation pathway is 
upregulated in prostate cancer. Prostate, 2005. 63(4): p. 316-23. 
18. Liu, Y., L.S. Zuckier, and N.V. Ghesani, Dominant uptake of fatty acid over glucose by 
prostate cells: a potential new diagnostic and therapeutic approach. Anticancer Res, 
2010. 30(2): p. 369-74. 
19. Lobo-da-Cunha, A., et al., Histochemical and ultrastructural characterization of the 
posterior esophagus of Bulla striata (Mollusca, Opisthobranchia). Microsc Microanal, 
2010. 16(6): p. 688-98. 
20. Andrews, R.M., et al., Reanalysis and revision of the Cambridge reference sequence for 
human mitochondrial DNA. Nat Genet, 1999. 23(2): p. 147. 
21. Pereira, L., et al., The diversity present in 5140 human mitochondrial genomes. Am J 
Hum Genet, 2009. 84(5): p. 628-40. 
22. Li, B., et al., Automated inference of molecular mechanisms of disease from amino acid 
substitutions. Bioinformatics, 2009. 25(21): p. 2744-50. 
23. Pereira, L., et al., Comparing phylogeny and the predicted pathogenicity of protein 
variations reveals equal purifying selection across the global human mtDNA diversity. 
Am J Hum Genet, 2011. 88(4): p. 433-9. 
24. Kloss-Brandstatter, A., et al., HaploGrep: a fast and reliable algorithm for automatic 
classification of mitochondrial DNA haplogroups. Hum Mutat, 2011. 32(1): p. 25-32. 
25. Costello, L.C. and R.B. Franklin, The clinical relevance of the metabolism of prostate 
cancer; zinc and tumor suppression: connecting the dots. Mol Cancer, 2006. 5: p. 17. 
26. Costello, L.C., et al., Zinc and prostate cancer: a critical scientific, medical, and public 
interest issue (United States). Cancer Causes Control, 2005. 16(8): p. 901-15. 
27. Ranasinghe, W.K., et al., The role of hypoxia-inducible factor 1alpha in determining the 
properties of castrate-resistant prostate cancers. PLoS One, 2013. 8(1): p. e54251. 
28. Maximo, V., et al., The biology and the genetics of Hurthle cell tumors of the thyroid. 
Endocr Relat Cancer, 2012. 19(4): p. R131-47. 
29. Maximo, V., et al., Mitochondrial DNA somatic mutations (point mutations and large 
deletions) and mitochondrial DNA variants in human thyroid pathology: a study with 
emphasis on Hurthle cell tumors. Am J Pathol, 2002. 160(5): p. 1857-65. 
30. Savagner, F., et al., Defective mitochondrial ATP synthesis in oxyphilic thyroid tumors. J 
Clin Endocrinol Metab, 2001. 86(10): p. 4920-5. 
31. Gasparre, G., et al., Disruptive mitochondrial DNA mutations in complex I subunits are 
markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci U S A, 2007. 
104(21): p. 9001-6. 
 
 
Role of MCTs in Prostate Carcinoma Pértega-Gomes N. 
 
133 
 
Tables 
Table 1.  Details of the immunohistochemical procedure used to analyze the expression of the 
different proteins. 
Protein  Antibody Company  
Antibody 
Dilution  
Positive 
Control  
Incubation 
Period  
Detection 
System  
MCT4 sc-50329 
Santa Cruz 
Biotechnology 
1:500 Colon tumor Overnight 
R.T.U. Vectastain 
Universal Elite ABC 
Kit, Vector, EUA 
MCT2 sc-50322 
Santa Cruz 
Biotechnology 
1:200 Muscle 
2 hours 
Ultravision 
Detection System 
Anti-polyvalent, 
HRP, Labvision 
Corporation, 
Freemont, CA 
CD44 156-3C11 Serotec 1:1000 Colon tumor 
GLUT1 ab 15309 Abcam 1:2000 
Head and neck 
tumor 
CAIX ab 15086 Abcam 1:2000 Stomach 
MCT1 sc-365501 
Santa Cruz 
Biotechnology 
1:500 Colon tumor 
Overnight 
R.T.U. Vectastain 
Universal Elite ABC 
Kit, Vector, EUA HIF-1α 610958 
BD 
Biosciences 
1:100 Glioblastoma 
GLUT12 ab 75441 Abcam 1:500 Rim Overnight 
Ultravision 
Detection System 
Anti-polyvalent, 
HRP, Labvision 
Corporation, 
Freemont, CA 
LDHV ab 53010 Abcam 1:1000 Colon tumor 
2 hours 
HKII ab104836 Abcam 1:750 Colon tumor 
PDK1 ab110025 Abcam 1:500 Stomach 
CD147 sc-71038 
Santa Cruz 
Biotechnology 
1:400 Colon tumor 
AMACR 504R-16 Cell Marque 1:50 Kidney 
ACOX3 sc-135435 
Santa Cruz 
Biotechnology 
1:250 Liver 
DBP 
DBP antibody was a gift 
from Dr. Gabriele Moller 
from HelmholtzZentrum 
mÜnchen. 
Ready to 
use 
Kidney 
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Table 2. Details of the Western-blot procedure used to analyze the expression of the different 
proteins. 
 Primary Antibody 
Protein 
Marker  
Reference Company  
Antibody 
Dilution  
Incubation 
Period 
Reactivity Reference Company 
CD44 156-3C11 Serotec 1:1000 
overnight 
anti-
mouse 
sc-2031 
Santa Cruz 
Biotechnology 
MCT1 sc-365501 
Santa Cruz 
Biotechnology 
1:500 
HIF-1α 610958 
BD 
Biosciences 
1:1000 
HKII ab104836 Abcam 1:2000 
PDK1 ab110025 Abcam 1:2000 
CD147 sc-71038 
Santa Cruz 
Biotechnology 
1:100 
MCT4 sc-50329 
Santa Cruz 
Biotechnology 
1:500 
anti-rabbit sc-2004 GLUT1 ab 15309 Abcam 1:800 
CAIX ab 15086 Abcam 1:2000 
LDHV ab 53010 Abcam 1:2000 
TOM20 sc-11415 
Santa Cruz 
Biotechnology 
1:5000 anti-rabbit 
 
UCP-2 sc-6525 
Santa Cruz 
Biotechnology 
1:400 anti-goat 
 
Actin sc-1616 
Santa Cruz 
Biotechnology 
1:5000 anti-goat sc-2020 
 
 
 
 
Table 3. Association between MCT1, MCT2, MCT4, CD147 and CD44 expressions in prostate 
tumours. 
 
 
 
 
   
MCT1   MCT4  MCT2  
n  
Positive 
(%)  p  
Positive 
(%)  p  
Positive 
(%)  p  
CD147      <0.001    <0.001    0.411  
Negative  283 39.6  
 
6.2  
 
34.7  
 
Positive  185 60.4     17.0     36.5     
CD44      <0.001    0.003    0.002  
Negative  274 35.8  
 
7.3  
 
21.8  
 
Positive  126 53.2     17.1     37.2     
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Table 4. Details of proteins expression regarding subcellular localization.  
 
Proteins sub- cellular Localization 
  BT PIN TT MT 
Proteins 
 
MCT1 PM (Fig. 2A,A1) PM (Fig. 2A,A2) PM (Fig. 2A,A3) PM (Fig. 2A,A4) 
MCT2 C (Fig. 2A,B1) C (Fig. 2A,B2) C (Fig. 2A,B3) C (Fig. 2A,B4) 
MCT4 C (Fig. 2A,C1) C (Fig. 2A,C2) C (Fig. 2A,C3) PM (Fig. 2A,C4) 
CD147 PM (Fig. 2A,D1) PM (Fig. 2A,D2) PM (Fig. 2A,D3) PM(Fig. 2A,D4) 
CD44 PM (Fig. 2A,E1) PM (Fig. 2A,E2) PM (Fig. 2A,E3) PM(Fig. 2A,E4) 
GLUT1 C (Fig. 2B,A1) C (Fig. 2B,A2) C (Fig. 2B,A3) PM (Fig. 2B,A4) 
GLUT12 C (Fig. 2B,B1) C (Fig. 2B,B2) C (Fig. 2B,B3) C (Fig. 2B,B4) 
LDHV C (Fig. 2B,C1) C (Fig. 2B,C2) C (Fig. 2B,C3) C (Fig. 2B,C4) 
HKII C (Fig. 2B,D1) C (2B,B2) C (2B,B2) C (2B,B2) 
PDK1 C (Fig. 2B,E1) C (2B,E2) C (2B,E3) C (2B,E4) 
CAIX C (Fig. 2B,F1) C (Fig. 2B,F2) C (Fig. 2B,F3) PM (Fig. 2B,F4) 
HIF NS NS N (Fig. 2B,G3) N (Fig. 2B,G4) 
AMACR C (Fig. 2C,A1) C (Fig. 2C,A2) C (Fig. 2C,A3) C (Fig. 2C,A4) 
ACOX3 C (Fig. 2C,B1) C (Fig. 2C,B2) C (Fig. 2C,B3) C (Fig. 2C,B4) 
DBP C (Fig. 2C,C1) C (Fig. 2C,C2) C (Fig. 2C,C3) C (Fig. 2C,C4) 
(NS) No staining. Staining at plasma membrane (PM), cytoplasm (C) or nucleus (N) in different 
prostate tissues.  
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Table 5. Correlations between key metabolic-related proteins expressions in prostate tumour 
samples and clinico-pathological data. 
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Table 6. mtDNA haplogroup affiliation of LNCaP and PC3 cell lines. All substitutions are 
transitions, and nomenclature reflects comparison versus the revised Cambridge Reference 
Sequence. 
Cell 
line 
Haplogroup Polymorphisms 
characteristic of the 
haplogroup 
Private 
polymorphisms 
Reverted 
polymorphisms 
LNCaP H26c 146-263-750-1438-4769-8860-
10562-11152 
13227-16129-
16519 
15326 
PC3 U5a1c 73-263-750-1438-2706-3197-
4769-7028-8860-9477-11467-
11719-12308-12372-13617-
14766-14793-15218-15326-
16192-16256-16270-16320-
16399 
195*-11120-
13802*-16172 
 
* These polymorphisms are characteristic of a very rare sub-haplogroup U5a1c1. 
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BT 
NT 
PIN 
TT 
MT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Heat map showing the groups benign tissue (BT), non-neoplastic tissue (NT), PIN 
lesions (PIN), tumour tissue (TT) and metastatic tissue (MT). The groups are 
red-colourcoded to the left of the heatmap, and protein names are given 
below each column.  
 
 
 
 
 
 
 
MT 
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PIN  
TT 
Role of MCTs in Prostate Carcinoma Pértega-Gomes N. 
 
141 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
 
 
 
 
Role of MCTs in Prostate Carcinoma Pértega-Gomes N. 
 
142 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
Role of MCTs in Prostate Carcinoma Pértega-Gomes N. 
 
143 
 
 
(C)  
 
Figure 2. Immunohistochemical expression of metabolic-related proteins in benign tissue (BT) PIN 
lesions (PIN), prostate tumour tissue (TT) and metastatic tissue (MT) (200x magnification).  
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LNCaP PC3 
MCT1 
MCT4 
CD147 
CD44 
GLUT-1 
GLUT-1 
MCT4 
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HIF1-alpha 
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C) D) 
A) 
Figure 3. (A) Western blot analysis of metabolic-related 
proteins showing different levels of expression in different 
prostate cancer cell lines. (B) Immunohistochemical 
expression of MCT4 and GLUT-1 in LNCaP and PC3 cell 
lines and metabolic characterization of prostate cell lines 
based on glucose consumption (C) and lactate production 
(D).  
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Figure 4. Effect of oxamic acid (OA) on cellular metabolism. The effect of OA on cellular 
metabolism was evaluated by extracellular glucose and lactate measurements. Glucose 
consumption and lactate production in 22RV1, LNCaP, PC3 and DU145 cell lines after the 
treatment with 40 mM of oxamic acid. Results were normalized to total biomass, at each time point. 
p values of the differences in the glucose consumption and lactate production were calculated in 
comparision with the control. 
A) B) 
C) D) 
E) F) 
G) H) 
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Figure 5. 
 
 
Figure 5. (A) Effect of thioridazine (TZ) in different prostate cancer cell lines. IC50 calculated for TZ 
in the different cell lines at different time points (24, 48 and 72 hours) is presented. (B) 22RV1, 
LNCaP, PC3 and DU145 cells viability (%) after 48 hours of exposure to increasing concentrations 
of phytanic acid. 
  
PDK1 
A B 
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M: Mitochondria; Li: Lipidic inclusions 
Figure 6. Prostate cancer cells at a structural level. LNCaP (Figure 6A) and PC3 (Figure 6B) 
cell lines are represented, respectively. In LNCaP cells many mitochondria (M) can be observed 
and tend to be localized close to lipidic inclusions. Several lipidic (Li) droplets are seen randomly 
distributed into the cytoplasm of cells. There is a moderate amount of granular endoplasmic 
reticulum and free ribosomes (Ri). Similar to LNCaP are the cells collected from prostate localized 
tumour (Figure 6C and 6D). In contrast, in PC3 cells (6B), small atypical mitochondria (M) were 
observed as well as many free ribosomes (Ri), but with no lipidic inclusions.  
  
A 
C 
B 
D 
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Figure 7. Analysis of Complex I activity. The activity of Complex I is proportional to the increase in 
absorbance at 450 nm. Activity mOD (milli-units of optical density) indicates that activity was 
measure at 450nm; Data correspond to two biological replicas done in duplicates. Bars, standard 
deviation; columns, mean. The asterisks indicates the level of statistical significance (*p<0.05); 
Data were subjected to one-way ANOVA and a posterior Tukey test. B) Analysis of global ATP 
levels. Data correspond to three biological experiments done in triplicates. Bars, standard 
deviation; columns, mean. Data were subjected to one-way ANOVA and posterior Tukey test. 
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Figure 8.  Analysis of UCP-2 protein expression.  A) Western blot analysis for the UCP-2 
protein, β-Actin as an exogenous control and TOM-20 as a control of mitochondrial loading. A 
representative immunoblot of two experiments is shown. B) Quantification of UCP-2 protein in the 
cell lines, expressed as density of UCP-2 band per density of TOM-20. C) Quantification of UCP-2 
protein in the cell lines, expressed as density of UCP-2 band per the density of the β-Actin. D) 
Quantification of TOM-20 protein in the cell lines, expressed as density of TOM-20 band per 
density of β-Actin. Bars, standard deviation; columns, mean. The asterisks indicates the level of 
statistical significance (**p<0.01). Data were subjected to one-way ANOVA and a posterior Tukey 
test. 
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Figure 9. Proteins involved in glycolytic and fatty acid oxidation pathway were also found to 
be aberrantly expressed in prostate cancer specimens. Heatmap showing mRNA levels of 
HK2, PDK1, CA9 and LDHA. AMACR, DBP and ACOX3 are also represented in the Varambally 
dataset (Figure 9A and 9B). Red: high; blue: low. Heatmap was generated using a galaxy-based 
CRI Bioinformatics Core Facility tool. SLC16A3 is aberrantly expressed in metastatic prostate 
cancer specimens. Heatmap showing mRNA levels of SLC16A1 (MCT1) (Figure 9C) , SLC16A7 
(MCT2) (Figure 9D) and SLC16A3 (MCT4) (Figure 9E) in the Varambally dataset.  
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C D E 
Role of MCTs in Prostate Carcinoma Pértega-Gomes N. 
 
151 
 
Figure 10. Kaplan-Meyer plots for SLC16A3 based on Glinsky et al., 2004. Recursive partitioning 
was performed using a galaxy-based CRI Bioinformatics Core Facility tool. 
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4.3.2 Exploitation of MCTs as potential  therapeutic targets in  prostate 
cancer . 
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Abstract 
The metabolic phenotype of many tumours switches from oxidative 
phosphorylation (used by the majority of normal epithelial cells) to aerobic 
(Warburg effect) or anaerobic glycolysis. This phenomenon significantly increases 
the rates of glucose consumption and lactate production, enabling tumours to 
meet their energy and biosynthetic demands even under conditions of low 
nutrients and oxygen. However the end-product of glycolysis, lactate, is a 
metabolic “dead end”, which if allowed to accumulate in the tumour cell can cause 
feedback inhibition of glycolysis, intra-cellular acidification and inhibition of cell 
growth. Therefore, pharmacological inhibition or disruption of lactate metabolism is 
a promising therapeutic strategy to target a range of human cancers. In this study 
we evaluate the effect of the compound CHC in different in vitro models of prostate 
cancer progression and aggressiveness and also we test the effect of specific 
inhibition of each MCT isoform using siRNA.  
We show that selective inhibition of lactate transport by MCT1 and MCT4 inhibition 
decreases the viability and proliferation of prostate cancer cell lines in normoxic 
and hypoxic conditions and might offer a novel mechanism for targeting the 
metabolic phenotype of tumours. However further studies need to be done in order 
to assess the effect of MCTs inhibition in the metabolism of prostate tumour cells. 
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Introduction 
Although prostate cancer (PCa) is one of the most incident cancers worldwide in 
men, there is a lack in terms of effective therapies against this disease being the 
existent ones invasive for patients. Thus, studies exploring novel therapies are 
urgently needed. 
Our previous reports are in accordance with some papers in the literature that 
describes prostate cancer as a tumour that does not rely mainly on glycolytic 
metabolism  but instead glycolytic metabolism is mainly found in the advanced 
stages of the disease [1,2].  As so, understanding the metabolism of these 
tumours can identify new molecular targets with clinical relevance.  
If MCTs can represent suitable targets in the metabolism of CaP is not well 
elucidated. An in vivo study from Kim and colleagues showed that MCT1 inhibition 
did not have a significant effect on tumour volume, although it was associated with 
increased necrotic fraction [3]. Since there are no reports yet about the true 
relevance of MCTs inhibition in the development and progression of PCa, it is 
important to invest in studies evaluating both the blocking and silencing of MCTs in 
this tumour.  
We aimed to evaluate the effect of MCT inhibition in PCa cell lines using CHC, a 
classical MCT1 inhibitor and also siRNAs to target different MCTs isoforms in 
different models of disease progression. 
 
Materials and Methods 
To understand the functional role of MCTs in tumor cells, we will evaluate the 
effect of MCT activity inhibition on tumor cell viability and proliferation in different 
prostate tumour cell lines. Activity inhibition studies were undertaken, using the 
MCT classical inhibitors, such as CHC, or RNAi specific for each MCT isoform.  
 
Cell Lines and Cell Culture 
Human prostate cell lines representing different relevant features of prostatic 
adenocarcinoma were used. The selected cells lines were obtained from ATCC-
Role of MCTs in Prostate Carcinoma Pértega-Gomes N. 
 
157 
 
American Type Culture Collection, MD, USA. Cell lines were grown in RPMI-1640 
cell culture medium supplemented with 10% Fetal Bovine Serum (FBS) (GIBCO®, 
Invitrogen,Carlsbad, CA) and 1% Penicillin-Streptomycin (P-S) (GIBCO®, 
Invitrogen, Carlsbad, CA).  
Downregulation of MCTs expression 
Silencing of MCT1, MCT2 and MCT4 expression was performed using siRNA from 
Qiagen. Final siRNA concentration used was 10nM. Lipofectamine RNAiMax 
(Invitrogen) was used as permeabilization agent, according to the manufacturer`s 
instructions.  
Drugs 
Alpha-cyano-4-hidroxycinnamate (CHC Sigma-Aldrich) was dissolved in dimethyl 
sulfoxide (DMSO Sigma-Aldrich) to perform the stock and working solutions.  
 Cell Viability and Proliferation Assays 
Different techniques were used to study the effect of MCTs inhibition in prostate 
cell lines. 
To study the effect of CHC in prostate cells, the cells were plated into 96-well 
plates and the effect of CHC treatment was determined at 24, 48 and 72h by 
sulforhadamide B assay (SRB, TOX-6;Sigma-Aldrich), according to the 
manufacturer`s recommendations. IC50 values (i.e., CHC concentration that 
corresponds to 50% of cell growth inhibition) were estimated from 3 independent 
experiments, each one in triplicate using GraphPad Software.  
To study cell proliferation and viability, after treatment with siRNA cells were 
seeded in twelve-well plates. Reverse transfection was carried out on the day of 
seeding; to assess the effects of drug treatments, cells were allowed to attaché for 
24 hours before treatment. Three and Six days after seeding, cells were harvested 
by trypsinization. In order to quantify both living and dead cells, the culture 
medium was saved and combined with the harvested cells. Cells were pelleted by 
centrifugation and resuspended in 500 ul PBS. Cell number and viability were 
determined using Beckman Coulter Vi-Cell. Duplicate samples were prepared for 
each experimental condition. Also using the Incucyte equipment growth curves 
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were obtained for different prostate cancer cell lines during one week with siRNA 
transfection at day 2. 
MTS assay was also used in a large variety of cell lines as a fast method to screen 
the effects of MCTs inhibition in cells viability. 
Metabolism Assay (Extracellular Glucose and Lactate Measurements) 
Cells were plated in 48-well plates and allowed to adhere overnight. Then cells 
were treated with 5 mM of CHC and the cell culture medium was collected after 8, 
12 and 24h for glucose and lactate quantification. Glucose and lactate were 
quantified using commercial kits (Roche and Spinreact, respectively), according to 
the manufacturer`s protocols.  
 
Results 
The use of CHC does not affect the lactate production in prostate cell lines. 
 The MCT inhibitor (CHC) decreased the total cell biomass of PNT2 and PC3 cells, 
while LNCaP was less sensitive along time (Figure 1). IC50 values were slightly 
higher in LNCaP than PC3 and PNT2 along time. The effect of CHC on prostate 
cell metabolism was evaluated using the IC50 values obtained by SRB assay at 48 
hours. MCT inhibition does not induce a decrease in lactate production in  prostate 
cell lines (Figure 2). 
 
MCTs 1, 2 and 4 specific inhibition differentially affect prostate cell lines 
under normoxic conditions 
The effect of the specific inhibition of different MCT isoforms, using siRNA, in the 
viability of prostate cell lines is shown in Figure 3. MTS results showed a 
significant decrease on prostate cell lines viability when MCT1 is inhibited. 
Regarding MCT2, its inhibition seems to affect namely PNT1a and PC3 cell lines 
whereas MCT4 inhibition affects PNT1a, C4-2 and PC3 cells viability. Curiously, 
LNCaP which was previously observed to be the less glycolytic of all the prostate 
cancer models was the only cell line that did not show any sensitivity to MCTs 
inhibition. In order to confirm the results obtained by MTS, vi-Cell counter 
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equipment was also used to assess the viability of cells after MCTs inhibition 
(Figure 4). This experiment was so far performed on PNT1a, LNCaP and C4-2B 
cells. 
The results obtained using vi-cell counter were in accordance to the ones obtained 
by MTS. PNT1a and C4-2B showed a decreased on viability when exposed to 
MCT1 and MCT4 inhibitors. Again, LNCaP showed no evident alterations in their 
viability when the different MCT isoforms were inhibited. 
MCTs 1, 2 and 4 specific inhibition differentially affect prostate cell lines 
under hypoxic conditions 
Due to the already mentioned importance of hypoxia with subsequent activation of 
HIF and its implications in tumour metabolism plus the early observation that 
MCT4 mRNA levels clearly increased in hypoxic conditions, we assessed whereas 
cells under hypoxic conditions will be more dependent on these transporters and 
so more susceptible to their inhibition. Figure 5 shows the effect of MCTs inhibition 
under hypoxic conditions in cell lines viability measured by MTS. 
Accordingly, in the results obtained by MTS assay an evident decrease in cell 
viability was shown in PNT1a and C4-2B when MCT1 and MCT4 are inhibited. 
Again, a decrease on LNCAPs viability with MCT1 inhibition under hypoxic 
conditions was observed (Figure 6) 
MCT1 inhibition affects the proliferation of prostate cell lines under 
normoxia 
In order to assess the effects of MCTs inhibition on the proliferation of prostate 
cancer cells, three different models of prostate cancer cell lines were used and the 
growth curves were obtained using the Incucyte equipment. The cells were 
incubated for one week and transfected at day two. Figure 7 shows the growth 
curves for LNCaP, C4-2 and C4-2B cell lines before and after MCTs inhibition. The 
arrow indicates the day in which cells were transfected. 
The cell models studied showed a decrease in cell proliferation after MCT1 
inhibition. Importantly, while previously LNCaPs showed no decrease on cell 
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viability upon MCTs inhibitor under normoxic conditions, a decrease in cell 
proliferation was observed when MCT1 was inhibited in this cell line.  
Discussion 
The increase in lactate production as a consequence of the high levels of 
glycolytic metabolism by tumour cells even in normoxic conditions is widely 
described in several types of cancer and monocarboxylate transporters have been 
described as upregulated in several tumours as a consequence of this change in 
cells metabolism. This fact makes MCTs attractive targets for cancer therapy, 
however, the knowledge on MCTs as potential targets in prostate cancer therapy 
stills scarce. 
We observed that MCTs inhibition using CHC appears not to affect glycolytic 
metabolism of prostate cells, supporting the lower dependence of prostate cancer 
on glycolytic metabolism. Importantly, PNT1a and PC3 were the cell lines that 
showed higher sensitivity to CHC inhibition although this inhibition did not affected 
glucose consumption or lactate production.   Being CHC a compound with much 
higher affinity for MCT1 than MCT4 these results are not surprising since our 
theory supports a lactate efflux through MCT4 in PC3 cells and not MCT1. Also 
the fact that the non-malignant cell line PNT1a showed higher levels of glicolytic 
metabolism and sensitivity to CHC might be explained by the fact that this cell line 
has a truncated Krebs cycle, relying less on OXPHOS than LNCaPs. Curiously, 
LNCaPs showed an increase in glucose consumption when MCT1 was inhibited. 
In theory we believe that MCT1 is being use for lactate uptake and so, the 
inhibition of MCT1 by CHC will lead to an increase demand of glucose to feed 
Krebs cycle since lactate uptake as a fuel was being blocked by the use of this 
drug. We have already some evidence that LNCaPs are able to consume lactate 
(data not shown), but further studies are being developed in order to prove this 
theory. 
Using siRNA to specifically inhibit different isoforms of MCTs we found out that the 
inhibition of different isoforms in different cell lines and under different environment 
conditions affect in different ways prostate cells. This complexity corroborates our 
previous hypothesis indicating that MCTs are activated differentky across prostate 
malignant transformation and so these results are complex and need to be 
interpreted considering the metabolic heterogeneity of prostate cancer disease.  
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However, in a general way we can say that even under normoxia or hypoxia MCT1 
seems to be a suitable target for prostate cancer cells, whereas MCT4 inhibition 
effect on cells viability and proliferation in more evident under hypoxic conditions.  
More studies are being developed in order to characterize the effect of MCTs 
inhibition accordingly to different phases of disease progression. 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Effect of CHC on total cell biomass of prostate cell lines along time (sulphorhodamine B 
assay).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Effect of CHC on glucose consumption and lactate production, along time, in prostate 
cancer cell lines. 
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Figure 3.  Effect of MCTs inhibition on cell viability measured by MTS assay on PNT1a, LNCaP, 
C4-2, C4-2B and PC3 cell lines. 
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Figure 4.  Percentage of viable cells after treatment with MCTs inhibitors on Day 3 and Day 6.  
 
 
   
 
Figure 5. Effect of MCTs downregulation on cell viability under hypoxic conditions measured by 
MTS assay on PNT1a, LNCaP, C4-2, C4-2B and PC3 cell lines. 
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Figure 6. Percentage of viable cells after downregulation of MCTs  on Day 3 and Day 6. 
 
 
 
 
 
 
 
 
Figure 7. Growth curves obtained using Incucyte equipment to assess the growth of cancer cells, 
namely LNCaP, C4-2 and C4-2B before and after MCTs inhibition. 
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CHAPTER 5. A ROLE FOR MCTs IN PROSTATE CANCER 
ENVIRONMENT  
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  5.1 CHAPTER OVERVIEW  
 
It is well established that solid tumours, including prostate cancer, exist under 
fluctuating oxygen tensions and are exposed to hypoxia. Tumour cells under 
hypoxia primarily use glucose for glycolytic energy production producing lactate 
which is expelled to the tumour microenvironment, allowing tumours to continue 
their glycolytic activity. Recent works postulated that lactate which was generally 
considered a waste product is preferred by tumour cells over glucose as primary 
energy source. If so, this aspect creates the perfect conditions for a symbiosis 
between anaerobic glycolytic cells and aerobic cells from the environment or vice 
versa.  
In the previous chapters we showed that prostate cancer cells do not rely primarily 
in glycolysis, but the metabolic switch to a high glycolytic phenotype seems to 
occur across malignant progression. In this perspective, we aimed to also evaluate 
the possible changes in the fibroblasts across malignant transformation and also if 
the theory on the “Reverse Warburg effect” could be suggested in prostate cancer 
model.  
In this chapter, we present results submitted for publication where we infer about 
interactions between CAFs and prostate tumour cells, analyzing the expression of 
key metabolic-related proteins in CAFs in relation to prostate cancer using a large 
series of prostate samples and assessing the clinico-pathological significance of 
this expression in order to infer a possible CAFs signature for PCa progression. 
We observed in CAFs a highly expression of MCT4 and CAIX corroborating the 
hypothesis of a “Reverse Warburg effect” in prostate cancer in which fibroblasts 
are under oxidative stress expressing CAIX, one of the best cellular biomarkers of 
hypoxia. Interestingly, we observed that alterations in metabolic-related proteins 
expression are already evident across malignant transformation and for the first 
time we observed that cases which show high MCT4 expression in CAFs with 
concomitantly strong MCT1 expression in PCa cells are associated with poor 
clinical outcome, namely presence of biochemical recurrence after surgery.  
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5.2    PUBLISHED RESULTS 
The results presented in this chapter were: 
(i) Submitted for publication as an original article in an international peer 
reviewed journal 
 
Pértega-Gomes N, Vizcaíno JR,Gouveia C, Lopes C. and Baltazar F. “A lactate 
shuttle system between tumour and stromal cells is associated with poor 
prognosis in prostate cancer”. 2013. 
 
(ii) Presented as poster in the following international scientific meeting: 
Pértega-Gomes N. Vizcaíno JR, Lopes C. and Baltazar F. “Comparison of 
Metabolic Pathways between cancer and stromal cells in prostate carcinoma. A 
role for Monocarboxylate transporters (MCTs) in tumour-stroma cross-talk.” at 
FEBS Advanced Lecture Course on Translational Cancer Research, Algarve, 
Portugal. 2011. 
 
(iii) Presented as poster in the following national scientific meeting: 
Pértega-Gomes N. Vizcaíno JR, Lopes C. and Baltazar F. “Monocarboxylate 
transporters 1 and 4 are upregulated in stroma cells surrounding malignant glands 
and PIN lesions” at Congress of Portuguese Society of Pathology, Porto, Portugal. 
2011. 
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5.3.1 A Lactate shuttle system between cancer and stromal cells mediated 
by Monocarboxylate transporters (MCTs) is associated with poor prognosis 
in prostate cancer 
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Abstract 
Objectives - Cancer cells are embedded in stromal cells, namely cancer 
associated fibroblasts (CAFs) that are now accepted as important players in 
cancer dynamics, being involved in the tumour growth and progression. Although 
various reports about this interaction exist, the clinico-pathological significance of 
this cross-talk is still largely unknown. In this study we aimed to characterize the 
expression of key metabolic proteins involved in the glucose transport, 
pyruvate/lactate shuttle system, glycolytic metabolism and fatty acid oxidation, in 
stroma (fibroblasts) across malignant transformation and differences between 
cancer cells and CAFs, assessing the clinico-pathological significance of this 
expression. 
Materials & Methods – Patients in the study were men who performed radical 
prostatectomy for prostate cancer treatment without any prior hormonal therapy.  
Prostate tissues were obtained from 480 patients with a median age of 64 years, 
who performed radical prostatectomy. Tissues were analysed for the expression of 
several key metabolic related proteins in glands and surrounding fibroblasts by 
immunohistochemistry.  Reliable markers of prognosis such as, pT stage and 
biochemical recurrence were assessed for each case. 
Results - We observed that prostate cancer cells do not seem to rely mainly on 
glycolytic metabolism, while we observed a high expression of MCT4 and CAIX in 
CAFs, suggesting that fibroblasts are under oxidative stress expressing CAIX, one 
of the best cellular biomarkers of hypoxia. Curiously, we observed that alterations 
in the expression of metabolism-related proteins are already evident across 
malignant transformation, suggesting a progressive alteration of CAFs from an 
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early stage. Additionally, and for the first time, we observed that cases that show 
high MCT4 expression in CAFs with concomitantly strong MCT1 expression in 
prostate cancer (PCa) cells are associated with poor clinical outcome, namely 
presence of biochemical recurrence after surgery and pT3 stage of the tumour.  
Conclusions - In sum, this work shows for the first time a clinico-pathological 
value for the lactate shuttle in prostate cancer, raising the possibility to explore 
further alterations in CAFs as prognostic factors and further support the use of 
MCT1/MCT4 as targets for PCa therapy.  
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Introduction 
It is well established that solid tumours, including prostate cancer, exist under 
fluctuating oxygen tension, being exposed to hypoxia [1,2]. Tumour cells under 
hypoxia use primarily glycolysis for energy, producing lactate, which is expelled to 
the tumour microenvironment, allowing tumours to continue their glycolytic activity 
[3,4]. Recently, Sonveaux et al. showed that lactate, which is generally considered 
a waste product, is preferred by oxidative tumour cells over glucose, as primary 
energy source [5]. If so, this aspect creates the perfect conditions for a symbiosis 
between anaerobic glycolytic cells and aerobic cells. 
Monocarboxylate transporters (MCTs) have been identified by our group to play an 
important role in various tumours [6] however, since they facilitate the transport of 
lactate in and out of the cells, their role in this stromal/epithelial cells symbiosis is 
also attracting interest. MCT1 is a high-affinity transporter and its expression 
seems to be regulated by multiple signaling pathways, microenvironmental 
parameters, changes in substrate concentration and pH. MCT4 is a low affinity 
transporter, which is abundantly present in highly glycolytic muscle cells and is 
also one of the many target genes of hypoxia-inducible factor 1 alpha (HIF- 1) [7]. 
Other targets of HIF-1 include glucose transporter-1 (GLUT-1), the main 
transporter involved in glucose uptake [8], lactate dehydrogenase V (LDHV), 
responsible for the conversion of pyruvate into lactate, pyruvate 
dehydrogenase kinase isozyme 1 (PDK1) that is responsible for the 
phosphorylation and consequently inactivation of pyruvate dehydrogenase PDH 
that contributes to transforming pyruvate into acetyl-CoA [9] and carbonic 
anhydrase IX (CAIX), a hypoxia-related protein involved in pH regulation [10]. We 
also aimed to evaluate alpha-methylacyl-CoA racemase (AMACR), pristanoyl - 
CoA oxidase (ACOX-3) and D-bifunctional protein (DBP) expressions since 
increasing data point to the importance of these fatty acid oxidation related 
proteins in prostate cancer [11,12]. 
In this study, we aimed to infer about possible metabolic interactions between 
CAFs and prostate cancer cells, by analyzing the expression of key metabolic-
related proteins in CAFs in relation to prostate cancer using a large series of 
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prostate samples. We also assessed the clinico-pathological significance of this 
expression to infer a possible CAFs signature for PCa progression. 
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Materials and Methods 
Patient sample selection 
Prostate cancer patients were selected according to the following criteria: 
availability of both tumour and normal tissue for each patient; presence of 
adequate amount of stroma in both normal and tumour tissues for efficient 
selection for tissue microarray construction (TMA); and absence of chemotherapy 
or radiotherapy. Prior to TMA construction, tissue morphology was assessed on 
HE slides. Formalin–fixed paraffin embedded tissues from 480 prostate cancer 
patients were retrieved from the archives of the Department of Pathology of Centro 
Hospitalar do Porto, Portugal. Stroma surrounding non-neoplastic glands, PIN 
lesions and malignant glands was also analyzed.  
Ethics 
The work has been approved by DEFI (Departamento de Ensino Formação e 
Investigação) Ethics Committee of Centro Hospitalar do Porto ref. no. 017/08(010-
DEFI/015-CES). 
Immunohistochemistry  
Samples organized into TMAs including 203 non-neoplastic, 176 PIN  and 480 
neoplastic tissues were analyzed for MCT 1 and 4, GLUT-1, GLUT-12, LDHV, 
PDK1, CAIX, AMACR, ACOX-3 and DBP expressions. Staining was evaluated 
using a combined score system, as previously described [13].  
Detailed information regarding immunohistochemistry technique is given in 
Table 1.  
Immunohistochemical evaluation 
IHC evaluation was performed evaluating the intensity and the extension of the 
staining, as previously described [13] and blindly by two independent observers, 
who were blind to the clinico-pathological data of the patients.  
Immunoreaction in TMA sections was evaluated for cytoplasmic and/or plasma 
membrane staining. Shortly, sections were scored semi-quantitatively as follows: 
0: 0% of immunoreactive cells; 1: < 5% of immunoreactive cells; 2: 5-50% of 
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immunoreactive cells and 3: > 50% of immunoreactive cells. Also, intensity of 
staining was scored semi-quantitatively as follows: 0: negative; 1: weak; 2: 
moderate and 3: strong. The final score was defined as the sum of both 
parameters (extension and intensity), and grouped as negative (scores 0-3) and 
positive (scores 4-6). Discordant results in different cores of the same case were 
scored as follows: average of extension plus highest intensity score. Discordant 
results were discussed in a double-head microscope. For statistical purposes, only 
moderate and strong immunoreaction final scores were considered positive. 
Discordant cases were discussed in a double-head microscope in order to 
determine a final score. 
 
 
Statistics 
Statistical analysis was performed using the SPSS statistical software 
(version 17.0, SPSS Inc., Chicago, IL, USA). All comparisons were examined for 
statistical significance using Pearson’s chisquare (χ2) test, being the threshold for 
significance p<0.05. 
Results 
Figure 1 shows the percentage of positive cases for each of the key metabolic-
related proteins studied in cancer-associated fibroblasts (CAFs) comparing to 
epithelial cells of malignant glands. We observed evident differences between the 
expression of these proteins in fibroblasts surrounding tumour and cancer cells. 
MCT1, MCT4, LDHV, PDK1, GLUT-1, GLUT-12, CAIX, AMACR, ACOX-3 and 
DBP are differently expressed between CAFs and tumour epithelial cells, while 
MCT1, LDHV, GLUT-1, GLUT-12, AMACR, ACOX-3 and DBP were exclusively 
expressed in prostate cancer cells. MCT4 and CAIX are more expressed in CAFs 
and PDK1 stained both malignant glands and CAFs. 
Additionally, we studied if fibroblasts exhibited differences in protein expression 
across malignant transformation by analyzing the expression of the same proteins 
in fibroblasts surrounding benign glands (BAFs), PIN lesions (PAFs) and finally 
cancer associated fibroblasts (CAFs).  
Role of MCTs in Prostate Carcinoma Pértega-Gomes N. 
 
180 
 
Figure 2 shows the heatmap representing the expression of MCT4, PDK1 and 
CAIX. The samples are divided in three groups: BAFs, PAFs and CAFs. The 
groups are red-colour coded to the left of the heatmap, and protein names are 
given below each column. For visualization purposes the expressions have been 
scaled between 0 and 3,accordingly to the final score of the staining for each case, 
as so, no staining (0), weak staining (1), moderate (2) and strong (3) staining are 
represented. 
All proteins that exhibited expression in CAFs are also present in some cases 
surrounding precursor lesions but not so evident surrounding benign glands. This 
is the case for MCT4 and PDK1, since CAIX curiously was also observed in 
fibroblasts surrounding non-neoplastic glands: benign glands and PIN lesion.  
Figure 3 shows representative immunohistochemical staining of the key metabolic-
related proteins in fibroblasts and prostate glands across malignant 
transformation, i.e. from fibroblasts surrounding non-neoplastic glands to 
fibroblasts surrounding PIN lesions and finally cancer associated fibroblasts. It is 
possible to observe an evident expression of MCT1 in the plasma membrane of 
prostate glands with no expression in the surrounding stroma. In contrast, we can 
see the increased expression of MCT4 in fibroblasts across malignant 
transformation with no staining in the prostate glands. PDK1 expression was 
detected in both glands and stroma, whereas CAIX was only detected in stroma 
with no staining in prostate glands. 
Associations between expressions of the metabolic proteins and clinico-
pathological data are presented in Table 2. Preoperative serum total PSA, clinical 
stage, perineural invasion and biochemical recurrence were selected for this study 
since these are some of the most important variables found to influence outcome. 
We observed that CAIX expression was associated with presence of biochemical 
recurrence after surgery (p=0.003) when expressed in CAFs and PDK1 showed a 
strong tendency to correlate with the presence of perineural invasion (p=0.069). 
Curiously, we found that the most interesting associations with the clinico-
pathological parameters were observed by considering the tumours that express 
MCT1 in tumour cells with concomitant expression of MCT4 in the surrounding 
CAFs . These cases were associated with the presence of biochemical recurrence 
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after surgery (p= 0.052) and pT3 stage (p=0.009) of the tumour. Additionally, 
cases negative for both or only with MCT1 present in the malignant glands, with no 
MCT4 in CAFs, showed no associations with clinico-pathological parameters (data 
not shown). Figure 4 shows a schematic representation of the the main findings 
regarding protein expression from radical prostatectomy specimens. Again, the 
lactate shuttle between CAFs and PCa cells that we found to exhibit clinico-
pathological relevance. 
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Discussion 
Several research groups have recently focused their interest on the role of cancer 
associated fibroblasts in the progression and metastization of prostate cancer, 
showing that a dynamic interaction between stroma and epithelium might play a 
critical role in this progression [14-17]. Thus, the critical role played by the cross-
talk between stroma and epithelium in carcinogenesis and prostate cancer 
progression has been increasingly recognized. In this work we provide evidence 
for the possible interactions between cancer cells and the surrounding fibroblasts 
in terms of metabolic cooperation, examining the expression of major proteins 
involved in cellular metabolism, focusing on differences between cancer cells and 
tumour-associated fibroblasts as well as in fibroblasts across malignant 
transformation and the possible clinico-pathological significance of this expression. 
In this study, an effort in order to categorize the protein expression of stromal cells 
associated with prostate cancer was made to categorize a compartment that is not 
well studied and will contribute to an improved understanding of prostate cancer.   
We firstly observed that there were significant differences between CAFs and 
tumour glands relative to the expression of key metabolic proteins. In particular, 
CAIX and MCT4 selectively label cancer associated fibroblasts in contrast to 
malignant glands where CAIX and MCT4 were only present in very few cases. On 
other hand, a distinct clear and strong membranous expression of MCT1 was 
noted consistently in cancer cells, suggesting a role in the transport of lactate in 
tumor cells from the acidic extracellular matrix, possibly meaning that lactate may 
be used as a fuel by oxidative cancer cells. Also, we observed that proteins 
involved in fatty acid oxidation are restricted to the tumour cells, which is 
compatible with the existence of a metabolic pathway different from glycolysis but 
compatible with OXPHOS in prostate cancer cells. 
The expression levels of GLUT1, a key transporter in the uptake of glucose by 
cells, are expected to define the rates of glucose influx into the cells. In the present 
study, CAFs did not show GLUT1 or GLUT-12 expression, but this presumably 
reflects the limits of immunohistochemical technique to detect membranous GLUT 
protein at the baseline concentrations present in CAFs. Similarly, as previously 
observed by us in prostate cancer cells, only very few cases were positive for 
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GLUT-1 and GLUT-12 and this expression was not even present at the plasma 
membrane, suggesting a low level of activity of these proteins.  Thus, assessment 
of other GLUT isoforms may be worth. Also, looking for other proteins already 
explored by us in cancer cells we found that also PDK1 expression, although not 
overexpressed in cancer associated fibroblasts, exhibited a tendency to correlate 
with the presence of perineural invasion which is considered a useful prognostic 
factor for predicting extra-prostatic extension and the involvement of surgical 
margin in the radical prostatectomy specimen.  
Interestingly, we also observed that protein expression in prostate fibroblasts 
changes across malignant transformation, suggesting that also the already 
existing stroma might suffer alterations and plays a role in this metabolic 
adaptation of cancer cells beyond the well studied role of newly formed stroma. 
From the above immunohistochemical findings, it seems that a contribution to 
overcoming the adverse microenvironment in prostate cancer may derive from 
well-organized metabolic domains composed of tumor cells and CAFs.  Our 
hypothesis is in agreement with the results of Fiaschi et al [18] that describe the 
metabolic reprogramming of CAFs towards the Warburg phenotype as a result of 
contact with prostate cancer cells. Using in vitro studies, they showed lactate 
production and extrusion by de novo expressed MCT4 in CAFs and also that 
prostate cancer cells upon contact with CAFs, were reprogrammed towards 
aerobic metabolism, with an increase in lactate upload via the lactate transporter 
MCT1. In agreement, pharmacological inhibition of MCT1-mediated lactate upload 
dramatically affected PCa cell survival and tumor outgrowth, however in this study 
they do not show any data regarding clinico-pathological associations and few 
cases were assessed. Another study by Giatromanolaki et al [19] suggests the 
opposite, also based on immunohistochemical findings, they described an energy 
recycling path between the aerobic stroma and the anaerobic cancer cells within 
the framework of the Warburg effect. Their conclusions are mainly based on the 
observation that LDH1 is evidently expressed in CAFs and the presence of MCT1 
that was also found mainly in prostate cancer cells was justified with a role in 
lactate extrusion and not in the uptake, as we believe it is.  We recognize the 
importance of assessing LDH1, however, in the present study we assessed for the 
first time MCT4 and CAIX as important markers of hypoxia in a larger series. Also, 
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we assessed important clinico-pathological parameters and we found associations 
with poor prognosis, raising once more the possible role of CAFs in disease 
management. We believe that these changes could be, and probably are more 
likely to be a byproduct of tumour biology with further influence on patients 
outcomes that need to be deeper explored. 
In summary, we examined cancer associated fibroblasts and differences between 
cancer cells and CAFs using tissues from 480 patients, showing the high 
expression of MCT4 and CAIX in CAFs and showing for the first time that there is 
a clinico-pathological significance for the MCT1 expression in tumour cells with 
concomitantly MCT4 expression in the fibroblasts of the same tumours.. In fact, it 
seems that the stromal expression of hypoxia regulated proteins is an adverse 
prognostic factor in prostate carcinomas, suggesting that tumor hypoxia may 
influence tumor-associated stromal cells in a way that ultimately contributes to 
patient prognosis. 
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Chapter 6. Further insights on MCTs regulation across prostate cancer 
progression    
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6.1 Chapter Overview 
In the previous chapters we show results suggesting an important involvement of 
MCTs in prostate cancer at a diagnostic, prognostic and therapeutic level. 
However, which mechanisms are involved on MCTs regulation across malignant 
transformation is still unknown. In this chapter we investigated MCTs expression at 
mRNA level in different in vitro models of prostate cancer progression and explore 
the potential cross-talk between Androgen Receptor (AR), the main driver of 
prostate cancer cell growth, and the different MCTs isoforms as well as the 
potential cross-talk between the key regulator of cellular energy homeostasis 
AMPK and MCTs expression. Also the effect on MCTs expression was also 
assessed in this chapter. 
The results presented in this chapter were obtained in collaboration with the 
 Urological Research Laboratory, Cancer Research UK Cambridge Institute 
University of Cambridge Li Ka Shing Centre and still unpublished.  
We show that MCT1 is expressed in all the models studied with no clear link 
between androgen stimulation/inhibition, AMPK stimulation/inhibition or hypoxia. In 
contrast, MCT2 was shown to be present at very low levels in prostate cancer cell 
lines and clearly downregulated by androgens with an apparent link with AMPK 
stimulation and no relation with hypoxia. Importantly, MCT4 appears to be strongly 
correlated with an aggressive phenotype, increasing its expression according to 
disease aggressiveness and although independent of androgen stimulation or 
inhibition, is highly dependent on the environmental conditions, being highly 
stimulated by hypoxic conditions and so a suitable target for cells under hypoxia. 
These results indicate that different MCT isoforms are differentially regulated 
across prostate malignant transformation, indicating that major drivers of these 
isoforms are distinct and so their identification in more detail is needed.  
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6.2 UNPUBLISHED RESULTS 
 
The results presented in this chapter were obtained in collaboration with 
the Urological Research Laboratory, Cancer Research UK Cambridge Institute 
University of Cambridge Li Ka Shing Centre. These results are considered 
preliminary data on the MCTs regulation in prostate cancer and are currently being 
studied more deeply. 
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6.2.1 Monocarboxylate Transporters (MCTs) regulation during prostate 
cancer progression 
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Abstract 
The androgen receptor (AR) is a key regulator of prostate growth and the principal 
drug target for the treatment of prostate cancer. Recently, AMP-activated protein 
kinase (AMPK) emerged as a potential target for cancer cell therapy due to the 
observation that activation of AMPK inhibits tumour cell growth.  On the other 
hand, we have the microenvironmental conditions, namely hypoxia which is known 
to increase the expression of genes with a crucial role in tumours progression and 
aggressiveness. However, how MCTs expression is affected by these different 
major drivers in prostate cancer is largely unknown. 
The aim of this work was to investigate MCTs expression at the mRNA level in 
different models of prostate cancer and their regulation during cancer progression 
and how they are affected by stimulation/inhibition of these major drivers of cancer 
progression. 
Our results showed that MCT2 was shown to be present at very low levels in 
prostate cancer cell lines and clearly downregulated by androgens with an 
apparent link with AMPK stimulation using metformin. Importantly, MCT4 appears 
to be strongly correlated with an aggressive phenotype, increasing according to 
disease aggressiveness and although independent of androgen stimulation or 
inhibition is highly dependent on the environmental conditions, being highly 
stimulated by hypoxic conditions and so a suitable target for cells under hypoxia. 
In contrast, MCT1 was shown to increase under hypoxic conditions but only in 
LNCaP cells. These results show that different MCT isoforms are differentially 
expressed during prostate cancer progression and that they are regulated in 
different ways. We believe that these changes reflect the metabolic demands of 
prostate cancer tumours during disease progression in which MCTs play an 
important role. These results also indicate that more accurate information into the 
metabolic variations across malignant transformation may help in the risk 
stratification of patients, with further implications in the management of the 
disease. 
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Introduction 
The androgen receptor (AR) is the main therapeutic target in prostate cancer. 
Androgen deprivation therapy (chemical castration) is an effective first-line therapy 
for prostate cancer, but despite good initial responses the recurrence of castrate-
resistant disease is common and ultimately fatal. AR is essential for cell viability, 
proliferation and invasion in both hormone-sensitive and castrate-resistant 
prostate cancer [1-3]. Clinical studies supported these findings by reporting the 
sensitivity of castrate-resistant prostate cancer to second-generation AR 
antagonists and hormone synthesis blockade [4-6].  
In castrate-resistant disease, where tumours are less sensitive to androgen 
depletion, AR activity is maintained by gene amplification [7], activating mutations 
[8,9] or signalling cross talk with other oncogenic pathways [10]. 
Massie CE et al  [11] discovered that CAMKK2 is a key effector of the AR, 
regulating glycolytic flux by activating AMPK-PFK signalling, which in turn drives 
anabolism and thereby controls prostate cancer cell proliferation and tumour 
growth. However, the role of AMPK in prostate cancer is controversial [12,13]; 
however, AMPK has an essential energy sensing role in cells and is critical in 
determining cell fate under stress conditions [14]. Therefore, the timing, level and 
cellular context of AMPK activation may have profound effects on the functional 
consequences of AMPK signalling. For example, in normal somatic cells AMPK 
has been shown to activate glycolysis via PFK and inhibit protein biosynthesis by 
decreasing MTOR activity [15-16]. In contrast, Massie CE data indicates that 
CAMKK2 enhances metabolic flux by stimulating AMPK phosphorylation without 
any effect on mTOR activity [11]. The mechanisms underlying this skewing of 
AMPK signalling in this context are unclear; however, it is possible that other 
targets of the AR or CAMKK2 may impact on these downstream pathways.  
 Hypoxia is a common feature of prostate tumours, leading to increased gene 
instability, reduced treatment response, and increased tumour aggressiveness. 
Tumour hypoxia is progressively emerging as a common feature of prostate 
tumours associated with poor prognosis. While the molecular basis of disease 
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progression is increasingly well documented, the potential role of hypoxia in these 
processes remains poorly evaluated [17].  
In this work we aim to study which mechanisms are involved in MCTs regulation in 
prostate cancer cells. For this purpose, we assessed the potential cross-talk 
between AR, the main driver of prostate cancer cell growth, and the different 
MCTs isoforms. Study of the potential cross-talk between the key regulator of 
cellular energy homeostasis AMPK (shown to regulate the activity of a number of 
transcription factors and involved in a different biochemical processes that might 
implicate the regulation of lactate production) and MCTs expression. Finally, we 
aimed to assess the effect of tumour microenvironment conditions, namely 
hypoxia on MCTs expression. 
 
Materials and Methods 
Cell lines and culture conditions 
The human prostate cancer cell lines 22RV1, LNCaP, C4-2,C4-2B,PC3, DU145 as 
well as the non-transformed prostate cell line PNT1a were obtained form America 
Type Culture collection.Cell lines were maintained in RPMI 1640 (Invitrogen) 
supplemented with 10% fetal bovine serum. Androgen treatments were carried out 
in phenol-red free RPMI 1640 (Invitrogen) supplemented with 10% of 
charcoal/dextrane treated FBS) (Hyclone). 
 
Drug treatments 
 
AICAR (Tocris Bioscience) and metformin (Sigma) were dissolved in sterile PBS 
and used at final concentrations of 0.5 mM and 2 mM, respectively. Compound C 
(Tocris Bioscience) was dissolved in DMSO and used at 2uM, final concentration. 
R1881 and bicalutamide (Sigma) were used at concentrations of 1nM and 10uM, 
respectively. 
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Results 
 Monocarboxylate Transporters 1, 2 and 4 expression in prostate cancer cell 
lines 
The expression pattern of MCTs isoforms were determined in a panel of prostate 
cell lines representing in vitro models of disease progression (Figure 1). PNT1a 
(non-transformed prostate), castrate sensitive (LNCaP) and castrate-resistant (C4-
2 and C4-2B) as well as AR negative prostate cancer cell lines (PC3 and DU145) 
were used. 
The obtained results show that mRNA levels for all MCTs were readily detectable 
by qrt-PCR in all 6 cell lines. It was interesting to observe that while MCT1 (Figure 
1A) and MCT2 (Figure 1B) expression changed in a similar way across the cell 
lines studied, MCT4 mRNA levels clearly increases according to the 
aggressiveness of the prostate cancer cell models (Figure 1C). This first 
observation immediately suggests that different isoforms are being differently 
recruited according to the cell model/stage of the disease. 
 
Effect of Androgen stimulation and inhibition on MCTs expression in 
prostate cell lines 
Being AR an important regulator of metabolic pathways in prostate cancer cell 
lines, regulating the expression of various genes involved in metabolism [11] we 
aimed to elucidate the potential cross-regulation between MCTs and AR signaling. 
With this purpose, cells were treated with R1881, a potent, non-aromatizable 
androgen which has also been used as a photoaffinity label for the androgen 
receptor and Bicalutamide a non-steroidal anti-androgen used in the treatment of 
prostate cancer and the mRNA expression levels for the different MCTs were 
assessed during different times. To account for possible differences between 
castrate-sensitive and castrate-resistant cells, these experiments were performed 
in both LNCaP and C4-2B cells. 
The results show that MCT2 clearly goes down with androgen treatment in both 
LNCaP and C4-2B cell lines. However, for MCT1 and MCT4 the effect of androgen 
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stimulation or inhibition was not so clear. Initially in both cell lines MCT1 seems to 
go down but at 48H an increase occurs in LNCaP cells. In contrast, MCT4 
behaves in a total different and opposite way in LNCaP and C4-2B. These results 
point to the idea that these isoforms (MCT1 and MCT4) might have another major 
driven mechanism, being not directly dependent on androgen 
stimulation/inhibition.  
These results were further confirmed looking at the available dataset from the 
group on LNCaP cell lines, showing that MCT2 expression definitely goes down 
with androgens (Figure 3). Also, AR binding sites were found near the gene and 
near the adjacent gene LRIG3 (which also is down-regulated), suggesting some 
locus-wide effect. Again, there were no major changes for MCT1 and MCT4 until 
24h of treatment, suggesting that AR is not the major regulator of these two 
isoforms. 
Effect of manipulating AMPK pathway on MCTs expression in prostate 
cancer cell lines 
Due to its role as key regulator of cellular energy homeostasis, AMPK has been 
largely explored in the cancer field. However, the role of AMPK stimulating drugs  
as enhancers or inhibitors of tumour growth is still controversial. The effect of 
AMPK on MCTs expression is largely unknown, however there are some studies 
reporting that AICAR, is a cell permeable activator of AMPK treatment decreases 
MCT1 and increased MCT4 mRNA levels in rat Sertoli cells [18]. Also, another 
study suggests that AMPK stimulation increases both MCT1 and MCT4 protein 
expression in mice plantaris muscle [19], however the link between AMPK and 
MCTs expression in the cancer context is not understood. 
Figure 4 shows the relative mRNA levels of MCTs when AMPK was stimulated by 
AICAR or Metformin and inhibited using Compound C in different in vitro models of 
prostate cancer and in the non-malignant cell line PNT1a. The results show that 
AICAR decreases MCTs mRNA levels in all the cell lines studied whereas in 
contrast Metformin has clearly the opposite effect on MCT2 mRNA levels. 
Regarding Compound C, the effects were not clear. It is shown to cause the 
opposite effect of AICAR and MTF on MCTs expression; however in most of the 
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cases Compound C maintains MCTs expression in the same levels as for 
untreated conditions (UT). 
The only striking results taking from this experiment was the clear effect of MTF on 
MCT2 expression. This result was quite interesting if we think that MCT2 has been 
downregulated by androgens. 
Again, the complexity of AMPK regulatory mechanisms is evident and also the 
doses of stimulators and inhibitors could cause different effects, as so, a further 
effort should be made in order to prove a possible link between AMPK and lactate 
transporters in prostate cancer.  
 
The Effect of Hypoxic microenvironment on MCTs expression in prostate 
cancer cell lines 
Tumour microenvironment is exposed to hypoxia which is one of the most 
recognized reasons for altered tumour metabolism. Perhaps the most important 
aspect of how cells respond to this unique microenvironment is the activity of the 
hypoxia-inducible factor 1 (HIF1) transcription factor. HIF has been massively 
explored in the cancer context and the link between HIF/hypoxia and MCTs has 
been already suggested, however in prostate cancer this correlation is not 
described. Figure 5 shows the expression levels of MCTs in LNCaP and C4-2B 
cell lines when grown in hypoxic conditions compared to normal oxygen levels. 
The results clearly show a great increase in MCT4 expression under hypoxic 
conditions compared to normoxia in both cell lines. MCT1 also seems to increase 
in LNCaP cells under hypoxia whereas for MCT2 no clear changes were observed 
under low oxygen conditions. 
 
Discussion:  
Our previous data so far suggest a metabolic switch from less aggressive in situ 
tumor to highly aggressive and metastatic prostate tumor, which seems to rely 
more on glycolytic metabolism. Also, these results suggest important ramifications 
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in the prostate cancer treatment where MCTs could represent suitable targets in 
different stages of the disease and together with other metabolic related proteins 
represent a valuable tool at the prognostic level (Pértega-Gomes et al, manuscript 
in preparation).  Although all the previous results point to a clear involvement of 
these transporters in prostate cancer, more work needs to be done in order to 
investigate and understand how MCTs are regulated and whether they represent 
promising targets for prostate cancer treatment in the in vivo context. 
The results herein presented confirm the idea that different isoforms are 
differentially expressed across prostate malignant progression. Also it shows that 
they are driven by different regulatory mechanisms.  
MCT4 mRNA levels clearly increase from LNCaP and C4-2 (low tumorigenic 
models) to C4-2B, PC3 and DU145 (highly tumorigenic models). Also, MCT4 
expression clearly increases when the cells are under hypoxia and consequently 
this protein was shown to be a possible target for prostate cancer cells that are 
under hypoxic conditions. These results are in accordance with our previous 
speculations for MCT4 involvement in malignant progression and aggressiveness.  
In contrast, MCT1 only showed a clear response under hypoxic conditions in the 
androgen dependent model LNCaP and no clear link with androgens or AMPK 
stimulation/inhibition was observed. MCT2 expression was shown to be 
independent of oxygen conditions; however it was androgen dependent, 
decreasing under androgen stimulation and increasing under androgen blockage. 
Another curious observation regarding MCT2 expression was that it increases 
when cells were treated with metformin. In the future, the molecular alterations that 
underlie MCT1 and MCT2 expression will be subject of further study, however 
these first observations already allow us to say that a complex regulatory 
mechanism is behind MCTs expression in PCa, indicating that different isoforms 
are being differently recruited across disease progression. 
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Figures 
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Figure 1.  Expression levels of MCTs 1, 2 and 4 in prostate-derived cell lines. RNA was 
isolated from PNT1a, LNCaP, C4-2, c4-2B, PC-3 and DU145 cells. RNA levels of MCT1 (A), MCT2 
(B) and MCT4 (C) were determined. For RNA quantification, n=3 ( (*) indicates that the difference 
in MCTs expression between the non-malignant PNT1a and the malignant models is statistically 
significant (p<0.005)). 
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Figure 2: Effect of Androgen stimulation and inhibition on MCTs expression. Levels of MCT1 
(A), MCT2 (B) and MCT4 (C) in LNCaP cell lines and levels of MCT1 (D), MCT2 (E) and MCT4 (F) 
in C4-2B cell lines after R1881 (R1881)  and bicalutamide  treatment (BIC) or with no treatment 
(UT) at different time-points are presented ( (*) indicates that there is a statistically significant 
different between MCTs expression in the UT vs treated conditions (p<0.005)). 
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Figure 3. Plot from the expression array with androgen treatment time-course. (Massie C.) 
  
MCT2 LRIG3 
MCT1 MCT4 
Role of MCTs in Prostate Carcinoma Pértega-Gomes N. 
 
211 
 
A                                                  B                                              C 
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Figure 4: Effect of AMPK activity manipulation (by pharmacological activators and 
inhibitors) on MCTs expression. Levels of MCT1 (A), MCT2 (B) and MCT4 (C)  in PNT1A, 
LNCaP, C4-2 and C4-2B cells untreated (UT)  treated with 0.5mM AICAR (AICAR) or 2 uM CC 
(CC)  for 48h; Levels of MCT1 (D), MCT2 (E) and MCT4 (F) in PNT1a, LNCaP, C4-2, C4-2B, PC3 
and DU145 cells treated with 2mM of metformin or 2uM CC for 48h ( (*) indicates that there is a 
statistically significant different between MCTs expression in the UT vs treated conditions 
(p<0.005)). 
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A                                               B                                            C 
D                                                   E                                              F 
 
Figure 5: Effect of hypoxic conditions (1% O2) on MCTs expression. Levels of MCT1 (A), 
MCT2 (B) and MCT4 (C) in LNCaPs under normoxic and hypoxic conditions ; Levels of MCT1 (D), 
MCT2 (E) and MCT4 (F) in C4-2B cells under normoxic and hypoxic conditions (*p<0.005). 
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CHAPTER 7. DISCUSSION AND FINAL CONSIDERATIONS 
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7.1 Discussion and Final Considerations 
 
As state before, recent models of carcinogenesis integrate the neo-Darwinian 
evolution, stating that phenotypic properties are retained or lost based on their 
contribution for cells survival with cell-environment interactions. This new concept 
of carcinogenesis was applied to explain the preference of cancer cells for the 
glycolytic phenotype, even in the presence of oxygen (Warburg effect). Thus, as 
cancer progression proceeds, mutations in tumour cells increase and traits that 
are found in invasive cancers, like the hyperglycolytic and acid-resistant 
phenotypes, arise as adaptive mechanisms to environmental proliferative 
constraints, such as hypoxia. Many players have been involved in these cellular 
adaptations; however, and although an important role of lactate transporters could 
be expected in the context of the Warburg effect, the knowledge on the role of 
MCTs in solid tumours and their potential as targets in cancer therapy is still very 
scarce. Also, it is important to keep in mind that in order to be used as therapeutic 
targets in cancer, MCTs must be differently expressed, either in quantity or in 
isoform. Thus, there is an urgent need to determine MCTs behavior during the 
carcinogenesis process.  
In this thesis, an important step forward was taken towards the possibility of 
exploiting MCTs as targets for prostate cancer therapy, accordingly to the stage of 
the disease. Firstly, a large series of human prostate tissue comprising benign 
tissue, PIN lesions, localized tumours and metastatic tissue was constructed. This 
series was well characterized and all the relevant clinico-pathological features 
were described and included in a detailed way in order to represent the 
heterogeneity of prostate cancer disease.  
The study of MCTs and CD147 expression in this well characterized series 
revealed an important association between MCT4 and CD147 expression and 
reliable poor prognosis markers of disease progression namely Gleason score, 
pT3 stage of the tumour and biochemical recurrence after surgery. This first 
finding was of great importance as, the tumours that present these characteristics 
have a more aggressive clinical behavior and, until now, do not have a specific 
molecular therapy. Additionally, in the same study we found MCT2 to be highly 
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expressed in the cytoplasm of prostate cancer specimens and PIN lesions 
however with no clinico-pathological associations suggesting a role in malignant 
transformation more than in the disease aggressiveness. 
Although we have found some important correlations, the presence of MCT1 in 
both tumour cells and non-malignant tissues as well as the absence of MCT4 at 
the plasma membrane lead us to hypothesize that prostate cancer might rely less 
than the majority of tumours on aerobic glycolysis. 
Moving forward in order to test this hypothesis, we found that in contrast to the 
majority of tumours that rely on glycolytic metabolism and in which the so called 
“metabolic switch” occurs in the malignant transformation, in prostate cancer this 
switch seems to occur only in the progression to the metastatic disease. Only the 
highly tumorigenic cell lines showed high levels of glucose consumption and 
lactate production in contrast to the low tumorigenic models. Importantly, when 
proteins involved in aerobic glycolysis were expressed in localized tumour, they 
correlated with poor clinical outcome, indicating an immunophenotype with 
prognostic value.  
The fact that prostate cancer might not fit in the typical model of high glycolytic 
transformation from benign to malignant glands, turned this work even more 
challenging in an attempt to contextualize the expression and consequently the 
role of different MCTs isoforms across prostate malignant transformation and 
progression. Being MCT2 highly expressed in localized tumour and MCT4 in the 
metastatic tissue this was indicative that the carcinogenic process leading to 
metastatic tumour, may require metabolic adaptations involving specific MCT 
upregulation and specific sub- cellular localization across different stages of the 
disease. Interestingly, MCT2 was found mainly in the localized disease with a high 
specificity and sensitivity to detect malignant glands, and its expression was 
shown to be similar to AMACR, a well established prostate cancer biomarker, 
being suggested as a putative prostate cancer biomarker, however, as well as 
AMACR, its expression was not correlated with poor prognosis parameters but it 
was present in high grade PIN (HGPIN) suggesting a possible role in the 
malignant transformation. Later, we found that this transporter co-localizes with the 
peroxisomal clusters and the formation of these clusters was observed from the 
non-malignant in vitro model PNT1a to 22RV1. The clusters as well as the co-
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localization of MCT2 with peroxisomes decreased across the different models of 
disease aggressiveness, suggesting again a possible role for this protein in the 
malignant transformation rather than aggressiveness of the disease. It is important 
to note that MCT2 has been the less explored isoform, possibly due not only to the 
fact that only few tumours exhibit an high expression of this isoform but also 
because it has not been reported at the plasma membrane, turning it not part of 
the classical Warburg effect model but a transporter with other but maybe not less 
important functions that needs to be unveiled. It was curious to find that MCT2 
mRNA levels consistently decrease with androgen stimulation, and increase with 
metformin, however these observations need to be further explored. 
Of all the three isoforms, MCT4 was the one showing the most striking changes 
across malignant transformation. Not only MCT4 expression increases across the 
different in vitro models of disease progression but also its localization changes 
from cytoplasm to the plasma membrane.  We showed that hypoxia might be the 
major driven mechanism underlying MCT4 expression across prostate progression 
and also that this isoform is a good target for cells under hypoxic conditions.   
 
As stated before, MCT1 was expressed both in the tumour cells and in vitro 
models that exhibited more and less glycolytic behavior; its specific inhibition 
showed that MCT1 is a suitable target for cells either under normoxia or hypoxia. 
This indicates that MCT1, besides being important in oxidative cancer cells, may 
also be important in glycolytic cancer cells. In fact, the kinetic parameters of MCT1 
make this isoform suitable for both the uptake and efflux of substrates. The role of 
MCT1 in both types of metabolic cancer cells makes it an even more interesting 
therapeutic target. It is not clear yet which mechanism drives MCT1, however we 
showed that hypoxia should have some influence since MCT1 mRNA levels 
increase in LNCaP under hypoxia, and in fact and since LNCaP was shown to be 
the cell line with less MCT4, MCT1 represents a good target for this model under 
hypoxia, however we should take into account that although MCT1 levels were 
higher in prostate cancer cells, normal prostate glands also express MCT1.  
Importantly, additional in vitro studies with MCT specific inhibition, evaluating 
parameters of aggressive behavior, such as migration, invasion and colony 
formation capacity will shed some light on the true value of MCTs. Indeed, MCT4 
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has already been associated with migration capacity. Of note, one should always 
remember that the main goal of MCT inhibition is the possible clinical application, 
so, the use of compounds that could have future clinical application, such as CHC 
and AstraZeneca compounds, ultimately offers a more advantageous approach.  
 
Considering MCTs in the light of the microenvironmental model of carcinogenesis, 
where they shall have a vital role in the emergence of both the hyper-glycolytic 
and acid-resistant phenotypes by enabling lactate efflux from cancer cells, as well 
as regulate the intracellular pH and, the recent model of metabolic symbiosis 
between glycolytic and oxidative cancer cells, where lactate plays a key role as the 
metabolic intermediate, MCTs are essential players in this process. It is proposed 
in this model that lactate release from glycolytic/hypoxic fibroblasts occurs through 
the low-affinity lactate transporter MCT4 and lactate uptake by the 
oxidative/oxygenated cancer cells occurs through the high-affinity MCT1 
transporter. Importantly, we explored for the first time the clinic-pathological 
significance of the establishment of this lactate shuttle observed that appeared to 
be linked to poor prognosis parameters namely the presence of biochemical 
recurrence after surgery, suggesting that immunohistochemical detection 
of proteins involved in the lactate shuttle may potentially prove to be useful as 
prognostic markers. In fact, and since we observed that CHC was able to 
decrease viability of prostate cancer cells but with no effect in glucose 
consumption or lactate production, corroborates the hypothesis that in prostate 
cancer the presence of MCT1 in the plasma membrane of cancer cells should be 
for the uptake of lactate instead of the efflux. 
With this work, some contribution was also made to understand MCT regulation by 
chaperones. Firstly, the regulation of MCT1 and MCT4, but not MCT2, by CD147, 
was supported by evidence on human tissues. Importantly, there was undetected 
expression of gp70 in prostate cancer samples, suggesting that a not yet identified 
chaperone is involved in MCT2 trafficking. In this regard we found PEX19 
interacting with MCT2, improving the knowledge on MCT2 regulation and function.  
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The data obtained so far points to the presence of different metabolic phenotypes 
across malignant transformation in which different isoforms of MCTs are 
differentially involved. As so, different isoforms of MCTs seem to be involved in 
different stages of prostate cancer progression. In one hand MCT1 and MCT2 
seemed important in the maintenance of localized disease whereas MCT4 being 
independent of androgen stimulation and highly dependent on hypoxia is related 
with the aggressive phenotype, pointing to the idea that targeting the different 
MCTs across prostate cancer disease progression seems promising.  
Much was achieved with this work but many other doors are now open that should 
be explored. Besides the more obvious lines that can be further explored, other 
directions can be taken, such as the study of other metabolic pathways like 
glutaminolysis, microenvironmental conditions like acidity and hypoxia, and other 
players in MCT regulation such as HIF-1a, AKT, c-myc and others. Importantly, 
since cell culture does not mimic all real tumour conditions, including O2 and 
nutrient limitation, key factors in metabolism, it is fundamental to assess the 
effects of MCT inhibition in an animal model, in what concerns tumour survival and 
aggressiveness. Therefore, in vivo studies evaluating the effect of MCT inhibition 
in, among others, tumour growth, angiogenesis and metastization are essential. In 
parallel, as MCTs are also important in physiological homeostasis, toxicity studies 
to determine MCT inhibition side effects will determine the actual potential of 
MCTs as therapeutic targets in cancer.  
 
In conclusion, the results herein presented encourage the exploitation of MCTs, as 
potential targets for prostate cancer therapy, and pave the way for further efforts to 
understand the role of MCTs in solid tumours that as prostate cancer might not 
rely mainly on glycolytic metabolism. Although major advances have been made 
with the present work, it elicits for many other studies to complement the present 
knowledge on MCTs’ role in prostate tumour survival and aggressiveness.  
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